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To my patients, I hope I can improve your care.

ABSTRACT
Chronic liver disease and liver cirrhosis are progressive diseases closely linked 
to metabolism and nutritional status. Weight loss is a result of negative energy 
balance and is therefore a good measure of risk of malnutrition. Screening and 
assessment of malnutrition in patients with liver cirrhosis is difficult because 
ascites and oedema are prevalent in late stages of liver cirrhosis. Accumulated 
fluid could make weight loss as an indicator of malnutrition inappropriate and 
malnourishment in obese patients can be challenging to identify. Knowledge about 
body composition, especially the presence of sarcopenia or sarcopenic obesity, 
is of great clinical value in the liver transplant setting. The scientific and clinical 
field is hampered by a lack of consensus on how to assess nutritional status in 
patients with liver cirrhosis. More research is needed to clarify the first part of the 
nutrition care process: nutritional assessment.
The aims of this thesis were to extend knowledge about nutritional assessment 
for patients with chronic liver disease before and after liver transplantation. The 
different parts of the nutritional assessment that are studied in my thesis are body 
composition methods, nutrition impact symptoms (NIS) and estimation of energy 
needs.
Study I and Study II were retrospective cohort studies based on patients that 
underwent liver transplantation between 2009-2012. Study III was a prospective 
cross-sectional study of patients undergoing evaluation for liver transplantation 
between 2016-2018. Study IV was based on a retrospective analysis of the early 
phase post liver transplantation for patients who underwent a liver transplanta-
tion between 2011-2018. Information on body composition was retrieved from 
dual-energy x-ray absorptiometry (DXA) scans and computed tomography (CT) 
scans together with anthropometric data, as well as data from questionnaires and 
information from indirect calorimetry. Additionally, information was obtained 
from medical charts and the local liver transplant register.
In study I, the influence of nutritional status on outcome after liver transplantation 
was studied. The prevalence of malnutrition was 2-20 % during the pre-transplant 
evaluation. The prevalence differed between genders and assessment methods. 
When measured with DXA, 20 % of the men and 5 % of the women were mal-
nourished. An association was found between fat-free mass index and occurrence 
of infections within 30 days after the liver transplantation. In study II we performed 
inter-method comparisons between muscle mass depletion measured with DXA 
and CT. Muscle mass depletion was found in 30-40% of the entire population, in 
women it varied between 13-69% with the different methods and in men between 
27-40%. Muscles in arms and legs measured with DXA had a strong correlation 
with muscles at the third lumbar vertebrae (L3) measured with CT but whole-body 
fat-free mass measured with DXA did not. In study III the aim was to assess the 
prevalence and severity of NIS and to explore associations with malnutrition and 
health-related quality of life (HRQOL). The prevalence of malnutrition was 32%. 
NIS were prevalent with 90% of the population presenting with one symptom or 
more and 51% of the population with four or more symptoms. A higher frequency 
of NIS was associated with malnutrition and worse HRQOL. Energy require-
ment early after liver transplantation was studied in study IV, and we found that 
the Harris & Benedict equation for predicting resting energy expenditure (REE), 
as well as the fixed factors 25, 30, 35 kcal/kg suggested in European guidelines, 
provided estimates of energy requirement that were too inaccurate to be of clinical 
value. There is a risk of both under- and overfeeding individual patients if fixed 
factors are used to estimate energy requirement early after liver transplantation. 
Measured REE was significantly associated (p < 0.05) with age, gender, Model 
for End-Stage Liver Disease score before liver transplantation, surgery time and 
graft cold ischemia time.
Together, the results from this thesis contributes to an understanding of the impor-
tance of a structured nutritional assessment as well as body composition assess-
ment in patients undergoing liver transplantation. The proportion of individuals 
who are malnourished or muscle mass depleted varies depending on the method 
used, NIS are prevalent and associated with malnutrition and worse health-related 
quality of life. Energy requirements should be measured and not estimated after 
liver transplantation. 
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11 PREFACE
As a registered dietitian, I started working at the Hepatology and Liver Transplantation 
Clinics in 2009, one year after I became a registered dietitian. Working with patients 
with chronic liver disease was difficult when I had little experience of the patient 
group. As a clinical dietitian I struggled with the nutritional assessment of the 
patients with ascites and oedema. After some years working in the liver team, it was 
obvious for my clinical eye when a patient needed nutritional support. However, 
it was not always possible to diagnose malnutrition when applying the common 
assessment factors weight, weight loss and low BMI. Even if my clinical experi-
ence told me that I needed to intervene, I did not have good ways to evaluate if the 
treatment was effective. All the things I learned in school seemed insufficient and 
I was frustrated of the lack of tools in the everyday clinic to assess my patients. 
All health professionals want to improve the care for their patients, and as a 
dietitian it is essential to perform a nutritional assessment before implementing 
nutritional interventions. I realised that the way to go if I wanted to be a better 
clinician was to go into research and explore new methods to perform nutritional 
assessment. This thesis is built on four studies putting together three of my main 
clinical frustrations: how do I assess malnutrition in patients suffering from chronic 
liver disease, which symptoms affecting the patients ability to eat are important to 
treat and how much energy do the patients really need after a liver transplantation?
22 INTRODUCTION
2.1 Nutritional status
There are more than 3 million hits on Google Scholar and 60 000 on PubMed for 
the phrase nutritional status. The phrase nutritional status can encompass different 
meanings. The MeSH term database defines it as “State of the body in relation to 
the consumption and utilisation of nutrients”. In this thesis, the phrase nutritional 
status refers to the state of the body, e.g. whether the individual is well-nourished, 
malnourished, obese, or underweight (Figure 1). The nutritional status can also 
refer to lack of micronutrients which is important but falls beyond the scope of this 
thesis. Nutritional assessment is the first part of the Nutrition Care Process (1). It is 
a systematic process of collecting and interpreting information about an individual’s 
nutrient intake, clinical signs, lifestyle, medical history and anthropometry. With 
this information it is possible to evaluate the nutritional status which then guides 
the nutritional interventions. Assessment of nutritional status can be a complex 
procedure. All methods are to some extent approximations and the validity and 
reliability of the method needs to be considered as well as what reference data the 
results are compared with. Nutritional assessment in patients with liver cirrhosis 
is especially challenging because of the common problem with fluid accumula-
tion. This thesis explores different methods to perform nutritional assessment in 
patients undergoing liver transplant evaluations and liver transplantation.
Figure 1. Aspects of nutritional status in patients with chronic liver disease
32.1.1 Malnutrition
Malnutrition can refer to either undernutrition or overnutrition; in this thesis it 
is used as a synonym for undernutrition. In Europe, 20 million individuals are 
at risk of malnutrition and the cost for the society is estimated to be around 120 
Billion Euros annually (2). Malnutrition increases both morbidity and mortality, 
and results in a functional impairment and lower quality of life (3-5). Malnutrition 
is recognised as part of the clinical symptoms of chronic liver disease, however 
there are many ways to measure it. One of the most common ways to diagnose 
malnutrition, The Subjective Global Assessment of Nutritional status (SGA) was 
introduced in 1987 by Detsky et al (6). SGA includes a technique built on patient 
history and a physical examination and has been thoroughly used in different 
studies investigating nutritional status in patients with liver cirrhosis (7-9). SGA 
and the liver-specific Royal Free Hospital-Global Assessment (RFH-GA) (10) 
are examples of bedside nutritional assessment techniques. Examples of single 
measure nutritional assessment techniques are mid-arm muscle circumference 
(MAMC) and hand grip strength (HGS). In the last two decades advanced methods 
have become more available to measure body composition such as bioelectrical 
impedance analysis (BIA), dual-energy x-ray absorptiometry (DXA) and cross-
sectional imaging assessment via computed tomography (CT) or magnetic reso-
nance imaging (MRI). A recent systematic review of 47 studies of patients with 
liver cirrhosis before and after liver transplantation found 32 different definitions 
for malnutrition (11). The prevalence of malnutrition in patients with liver cirrhosis 
is highly dependent on assessment method as well as severity of the liver disease, 
and reported frequencies of malnutrition vary between 5-99% (12). 
During the last decade major nutrition organisations have proposed different defini-
tions of malnutrition. The European Society for Clinical Nutrition and Metabolism 
(ESPEN) describe malnutrition as “a state resulting from lack of intake or uptake of 
nutrition that leads to altered body composition (decreased fat free mass) and body 
cell mass leading to diminished physical and mental function and impaired clinical 
outcome from disease” (13). Malnutrition has different origins, and according to 
ESPEN, there are several subgroups of malnutrition. Malnutrition can be disease-
related with or without an inflammatory process or it can be hunger-related (13). 
Throughout the years, many different criteria on how to diagnose malnutrition 
have been suggested. The American Society for Parenteral and Enteral Nutrition 
(ASPEN) and The Academy for Nutrition and Dietetics published a consensus 
statement in 2012 suggesting that no single parameter is definitive for malnutrition 
in adults (14). Two or more of the following six characteristics should be present 
to diagnose malnutrition: insufficient energy intake, weight loss, loss of muscle 
mass, loss of subcutaneous fat, localised or generalised fluid accumulation that 
may sometimes mask weight loss and diminished functional status as measured 
4by hand-grip strength. The most recent criterion was suggested by The Global 
Leadership Initiative on Malnutrition (GLIM) who published a consensus report 
from the global clinical nutrition community in 2018 (15), where both a pheno-
typic and a etiologic criterion need to be present to diagnose malnutrition (Figure 
2). The phenotypic criterium involves non-volitional weight loss, low body mass 
index or reduced muscle mass. The etiological criteria are reduced food intake or 
assimilation, inflammation or disease burden.
Figure 2. GLIM diagnostic scheme for screening, assessment, diagnosis and grad-
ing of malnutrition. 
From Cederholm et al. GLIM criteria for the diagnosis of malnutrition - A consensus report 
from the global clinical nutrition community Clin Nutrition. 2019 Feb;38(1):1-9. Doi: 10.1016/j.
clnu.2018.08.002. Reprinted with permission.
52.1.2 Sarcopenia and muscle mass depletion
Sarcopenia was originally a term used to describe the loss of muscle mass during 
normal ageing. Sarcopenia can be defined as: “a syndrome of its own character-
ised by the progressive and generalised loss of skeletal muscle mass, strength and 
function (performance) with a consequent risk of adverse outcomes”(13). The 
amount of skeletal muscle mass is influenced by both age and gender. In healthy 
adult individuals, the skeletal muscle mass is relatively stable, and after the age 
of ~45 years skeletal muscle mass starts to progressive decline (16) (Figure 3). 
Figure 3. The relationship between skeletal muscle mass and age. 
From Janssen et al, Skeletal muscle mass and distribution in 468 men and women aged 18-88 
yr, J Appl Physiol (1985). 2000 Jul;89(1):81-8 (16). Reprinted with permission.
Primary sarcopenia is the term suggested for age-related loss of muscle mass 
while secondary sarcopenia can appear secondary to a systemic disease such as 
organ failure or malignancy (17). Secondary sarcopenia can appear in all ages. 
The causes of sarcopenia are multifactorial and can be a combination of aging, 
disease, inactivity and malnutrition. The European Working Group on Sarcopenia 
in Older People (EWGSOP) first recommendation on how to diagnose sarcopenia 
put low muscle mass as a mandatory criteria for the diagnose (18). The sarcope-
nia diagnose is confirmed if low muscle mass is found in combination with either 
low muscle strength or low physical performance. In a review of 50 articles of the 
relationship between body composition, muscle strength and functional decline in 
older people, muscle strength and obesity were associated with functional decline 
6but low muscle mass was not (19). The recently updated recommendations from 
EWGSOP on how to diagnose sarcopenia (17) emphasise the importance of declin-
ing muscle function. In the updated diagnostic scheme to diagnose sarcopenia, the 
first step is to measure muscle strength. If muscle strength is low, the next step is 
to measure if muscle quantity or quality is low. If these two criteria are met the 
sarcopenia diagnosis is confirmed. After that, physical performance should be 
tested. Sarcopenia is considered severe if a person has low muscle strength, low 
muscle quantity or quality and low physical performance. It can be difficult to 
identify whether sarcopenia is primary or secondary. In this thesis the term sar-
copenia incorporates both primary and secondary sarcopenia. Sarcopenic obesity 
is the combination of loss of skeletal muscle mass and obesity. It should be noted 
that several studies performed on patients with liver cirrhosis use the term sarco-
penia for patients with low muscle mass but without any measurement of muscle 
strength or physical performance (20-23).
Muscle mass depletion describes the depletion of muscle mass compared to a ref-
erence population. The determinants of muscle mass in healthy subjects are age, 
gender, body region and fat mass (24). Measures of skeletal muscle mass should 
be normalised for height, and ethnicity-specific cut-offs are recommended (24). 
Because of the decreasing amount of muscle mass with age, it can be advantageous 
to use age-specific reference values when presenting how many individuals in a 
population is suffering from low amount of muscle mass. 
Both sarcopenia and frailty are acknowledged as important determinants for waiting 
list mortality (25, 26) in the liver transplant candidate. Frailty is a state of vulner-
ability and limited reserve capacity. This leads to reduced capability to withstand 
acute decompensating events and therefore frailty is a risk factor for dependence 
and disability. In liver transplantation candidates, the concept of physical frailty 
includes functional performance, functional capacity, and disability (27). In the 
studies included in this thesis neither sarcopenia nor frailty was evaluated because 
of the lack of data on muscle strength and physical performance in the majority 
of the study populations.
2.1.3 Adipopenia
The body has two main energy reserves, fat and muscles, that can be used in lack 
of energy from nutrient intake. Fat mass constitutes adipose tissue as well as fat 
in other parts of the body such as in the liver (28). Adipopenia is the depletion 
of adipose tissue. Visceral and subcutaneous tissues constitute the adipose tissue 
(29) and can be measured separately with imaging techniques (28), while DXA 
measures the entire fat mass in the body. In cirrhosis research, sarcopenia has been 
thoroughly explored in the last decade however adipopenia have not received a 
7lot of attention. Adipopenia is more frequent in females while muscle loss is more 
characteristic for male patients with liver cirrhosis (30, 31). The cause for these 
gender disparities in body composition is not fully understood. Ebadi et al found 
low subcutaneous adiposity to increase mortality risk in females with liver cirrhosis, 
even after adjusting for Model for End-Stage Liver Disease (MELD) score, but 
low skeletal muscle index did not (32). In compensated patients, lower visceral 
adipose tissue index was associated with 12-month decompensation in both male 
and female patients (33). Adipopenia can be highly relevant for female patients 
with liver cirrhosis and needs further exploration in future studies.
2.2 Nutritional assessment
2.2.1 Methods for body composition measurement
In the clinical setting, bedside anthropometric measurements such as body mass 
index (BMI), mid-arm circumference (MAC) and triceps skinfold thickness (TSF) 
are common and easy to use. BMI is a mathematical formula indicating over or 
underweight, but it provides no further insight into actual quantities of muscle mass 
or fat mass. Anthropometric measurements, such as MAMC, which is calculated 
from MAC and TSF, are time-efficient and the cheapest way to measure body 
composition. However, the reproducibility of TSF measurement is low because 
the accuracy depends on the investigators skill (34). 
BIA, DXA, CT and MRI are more technically advanced alternatives to measure 
body composition. There are also more complex methods such as underwater den-
sitometry, air displacement plethysmography and isotope dilution but those are 
methods mainly used for research. Standardised measurements of central muscle 
mass by CT or MRI have in recent studies shown potential value, but cost-effective 
alternatives are needed. DXA is a less expensive alternative that involves minimal 
radiation exposure. Assessment of muscle mass with CT, and to some extent also 
with DXA, has attracted much interest in recent years in patients with chronic 
liver disease (35-38). New clinical practice guidelines for nutrition in chronic liver 
disease by The European association for the Study of the Liver (EASL) were first 
presented in April 2018 (39). The guidelines recommend assessment of muscle 
mass with either CT or with DXA, but do not give any advice about whether the 
different methods provide comparable results when patients are assessed, or on 
how to compare outcomes in different studies. An overview of each of the meas-
urement methods advantages and disadvantages is presented in Table 1. 
8Table 1. Nutritional assessment methods of anthropometry, body composition 
and muscle function
Nutritional assessment 
method Strengths Drawbacks
Body weight
Weight change
BMI
Low cost
Simple to perform
Easy to reproduce
Influenced by body fluid 
changes 
Cannot identify obese patients 
at risk for malnutrition
Anthropometric measure-
ments; triceps skin fold 
 measurement, upper arm 
muscle circumference
Low cost
Bedside methods
Influenced by body fluid 
changes
Low interrater reliability
Low specificity and low 
sensitivity
Functional tests: handgrip
strength, sit-to-stand test,
6-minute walk
Provides insight into level 
of frailty
Can be affected by underlying 
disease or comorbidities 
Not a direct measure of 
nutrition
DXA High precision and 
accuracy
Can measure body 
 composition for both the 
whole body and parts of 
the body (40).
Differentiates between FM, 
FFM and bone
Safe
Not a bedside method
Cannot be used for very tall or 
severely obese patients
Changes in the body’s amount 
of water appears as a change 
in the amount of lean body mass 
in repeated measures (41).
Differences in software 
between manufacturers
CT/MRI Can determine tissue 
quality
High precision
Can identify sarcopenic 
obesity
Needs special software to 
quantify body composition
Often studies a single slice 
at L3 and extrapolates to 
whole-body, risk of over/ 
underestimating muscles 
Radiation exposure
BIA Can be used bedside
Can be portable
Non-invasive
Inexpensive compared to 
DXA/CT/MRI
Influenced by body fluid 
changes
Equation not validated for liver 
cirrhosis population
Air displacement 
plethysmography
Good reliability and validity
Non-invasive
Expensive equipment and not 
available in most centres
Limited literature in cirrhosis
Dilution techniques Can quantify total body 
water
Expensive equipment and not 
available in most centres
Time-consuming
Adapted from Di Sebastiano et al (42). BMI; body mass index, DXA; dual-energy x-ray 
 absorptiometry, FM; fat mass, FFM; fat-free mass, CT; computed tomography, MRI; magnetic 
resonance imaging, BIA; bioimpedance analysis 
9Different components of the body tissues are measured in body composition 
analysis. Two-component models divide the body into fat mass (FM) and fat-free 
mass (FFM) while multi-component models divide the body into three or more 
components (43). In the two-component model, equations are used to estimate 
the percentage of body fat from the body’s density. These equations assume that 
the density of FFM is 1.1 g/cm³ and the density of FM is 0.9 g/cm³. A potential 
consequence of using equations is a systematic over or underestimation of body 
components (44). Multicomponent models take into account individual variations 
in amount of fluid or the amount of minerals in the FFM (43). Therefore, multi-
component models generally provide more accurate estimates than two-component 
models. The four-component model (body weight, body volume, total body water 
and bone minerals) is considered most accurate for determining body composition 
(45) but it requires methods such as densitometry and isotope dilution techniques 
that are only available in certain centres and these methods are not used in clini-
cal practice.
2.2.2 Dual-energy x-ray absorptiometry
DXA separates the tissue into three compartments: bone mineral, lean soft tissue 
and fat mass. FFM constitutes of water, protein, glycogen, soft tissue minerals, 
and bone minerals. The lean soft tissue is the difference between FFM and bone 
minerals (46). DXA can measure body composition of the whole body but also 
of different regions of the body (40). During a DXA-measurement two X-rays 
with different levels of energy are sent through the body. DXA measures the ratio 
of photon attenuation at the two designated main energies. The X-rays will be 
weakened to different degrees depending on what kind of tissue the beams are 
hitting, and the information is then used to calculate body composition. DXA has 
a good precision, around 1-2 % (47) and reproducibility of FM is approximately 
1 % in adult patients. The radiation dose required for a whole-body measurement 
using DXA is 5-7 µSv (48). Different DXA machines use different techniques, 
either fan-beam or pencil-beam. A fan-beam corrects for the beam magnification. 
The main downside of DXA when it comes to liver disease is that it misclassifies 
changes in the fluid status as a change in lean body mass (41). 
2.2.3 Computed tomography
CT as a method to measure body composition was developed around 40 years ago 
and was presented as a promising method in 1995 (49). Different tissues generate 
different attenuations when the X-rays pass through tissues, expressed as  attenuation 
relative to air and water. Air is defined as -1000 Hounsfield units (HU) and water 
as 0 HU. At the image reconstruction at CT imaging each of the image pixels is 
assigned a HU. The obtained HUs of the imaged tissue can at image processing 
be used to determine the body composition. 
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The use of CT to measure body composition started to be used more wide-spread 
in clinical cancer research in 2008 (50) and the first study in patients with liver cir-
rhosis was published in 2010 (51). During the last nine years more than 75 studies 
have been published using CT to quantify muscle mass in patients with cirrhosis. 
Even if the method has attracted a lot of interest in the research community there is 
still no established methodology which is uniformly used. A variety of techniques 
is in use, including different software programs, thresholds, slice thicknesses, 
and tube voltage. Many studies use CT scans performed for clinical reasons and 
there is a discrepancy in whether contrast-enhanced scans or unenhanced scans 
are included, and different phases of the scans have been used. Also, different 
muscles are measured. For example, in some studies the axial and the transversal 
psoas-muscle are quantified, and other studies measure all spinal and paraspinal 
muscles. There is also heterogeneity in which cut-offs for low skeletal muscle mass 
are used. Published cut-offs are based on different types of populations: patients 
with end-stage liver disease (20) and those with cancer (52).
2.2.4 Energy requirement
Estimating or measuring energy requirement is an important part of the nutritional 
assessment. Prediction equations (e.g. Harris & Benedict equation) or fixed factors 
(e.g. 30 kcal per kilogram body weight) is often used to estimate energy require-
ment in the clinical setting. Resting energy expenditure (REE) can be measured 
with indirect calorimetry (IC). Energy in the form of carbohydrate and fat provide 
the body cells with fuel for vital functions and forms heat, water and carbon diox-
ide. The body’s waste products from metabolism, carbon dioxide and water, are 
removed via the exhaled air. IC measures energy metabolism and uses a technique 
in which energy metabolism at rest is calculated by measuring the consumption 
of oxygen and carbon dioxide production by analysis of the exhaled air (53). 
REE is the sum of organ and tissue metabolic rates (54). To calculate total energy 
expenditure (TEE) a physical activity level (PAL) is added to REE. 
After liver transplantation, some patients have an altered metabolism, often 
a hyper metabolism (55, 56). To calculate energy requirement based on body 
weight or prediction equations can therefore be misleading. Previous guidelines 
recommended using the Harris & Benedict equation  (HB) for calculating REE in 
patients with liver cirrhosis (57). HB was originally developed in 1918. A revision 
in 1984 confirmed its accuracy in healthy people with a precision of +/- 14 % but 
HB is unreliable in malnourished patients (58). Different fixed factors (25, 30 and 
35 kcal/kg body weight) to calculate energy requirements after liver transplantation 
have been suggested in recent guidelines from ESPEN and EASL (39, 59, 60).
11
2.2.5 Nutrition impact symptoms
A crucial part of the nutritional assessment is identifying barriers for eating. 
Disease-related decrease in dietary intake can be attributed to a disturbance of 
appetite control and a variety of symptoms such as nausea, vomiting, diarrhoea, 
constipation, depression, anxiety or pain. Aggregated together, these symptoms are 
called nutrition impact symptoms (NIS) (61). NIS can potentially lead to reduced 
food intake and thereby contribute to weight loss and risk of malnutrition. Several 
studies have described how patients with liver diseases suffer from symptoms that 
affect the ability to eat such as reduced appetite, nausea and early satiety (62-64). 
How much these symptoms affect nutritional status or quality of life in patients 
under evaluation for liver transplantation has not been previously studied. 
The prevalence of NIS has been studied in patients with cancer, unique individual 
symptom profiles are suggested to require specific intervention to improve nutri-
tional status (65). NIS such as loss of appetite, difficulty in chewing, dry mouth, 
thick saliva and pain were associated with decreased food intake (65). One study 
found that NIS led to reduced energy intake and weight loss (61). In another study, 
79% had some symptoms that resulted in eating difficulties one month after start 
of chemotherapy and the incidence of NIS was associated with a lower quality 
of life and a poorer performance status (66). Omlin et al. examined NIS with a 
12-item NIS checklist and found that 29% had one symptom or more, 21% had 
two symptoms and 13% had three or more symptoms (67). 
In a recent study on patients with gastroenterological and liver diseases, specific 
NIS such as difficulties swallowing, poor appetite, early satiety and food tasting 
bad were found to be correlated with low hand grip strength and weight loss (68). 
NIS have also been investigated in patients with renal disease were NIS was related 
to nutritional status and mortality (69). NIS is common in patients with chronic 
obstructive pulmonary disease and malnourished patients have more NIS (70). 
NIS have not been thoroughly investigated in healthy subjects. Some studies on 
prevalence of different symptoms, mainly gastrointestinal symptoms, exists with 
data from the general Swedish population. In a study of 268 randomly selected 
adults, with the aim to investigate bowel habits, bloating, straining, urgency, and 
feelings of incomplete evacuation were common findings among both females 
and males (71). In a study with the aim to establish population-based data to use 
as a reference from results on studies with patients with head and neck cancer, the 
prevalence of symptoms of nausea/vomiting was 3.5%, pain 16.6%, appetite loos 
5.1%, diarrhoea 5.8% and constipation 5.2%. in a random sample of the Swedish 
adult population (72). 
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2.3 Liver cirrhosis
Chronic liver disease involves a wide spectrum of different diseases that can result 
in chronic liver injury. There are toxic diseases such as alcoholic liver disease, 
autoimmune diseases like autoimmune hepatitis, primary biliary cholangitis and 
primary sclerosing cholangitis (PSC), or viral diseases such as hepatitis B and 
C or metabolic disorder caused by fat accumulation such as non-alcoholic fatty 
liver disease. 
Liver cirrhosis is the last stage of chronic liver disease that develops when scar tis-
sue, fibrosis, replaces normal, healthy tissue in the liver. Liver cirrhosis is initially 
asymptomatic (compensated). As the disease progresses, different complications 
such as portal hypertension, oesophageal varices, ascites, hepatic encephalopathy 
and hepatorenal syndrome arise (decompensated) (73).  For patients with compen-
sated cirrhosis, one-year mortality is approximately 5.4% compared to 20.2% for 
those with decompensated liver cirrhosis (74). In Sweden, the age-standardised 
death rate for liver cirrhosis is 4.9 per 100 000 deaths in 2010 and about 0.1% of 
the European population suffers from cirrhosis (75). The Child-Pugh scoring sys-
tem is one way to predict mortality (76). The Child-Pugh score has three stages A, 
B and C where C is the most severe disease. Another score is MELD which can 
range between 6 to 40, where a higher score indicate a higher mortality risk (77). 
The populations in the studies in this thesis include patients with chronic liver 
disease and the majority has liver cirrhosis. The phrase “chronic liver disease” 
encompasses all stages of liver disease except acute liver failure and the phrase 
“liver cirrhosis” is specific for when cirrhosis has developed.
2.4 Liver transplantation
Liver transplantation is a standard clinical treatment for patients with many types 
of liver diseases and liver transplantation is the only life-saving treatment for 
patients with severe liver disease. The main indications for liver transplantation in 
Europe are liver cirrhosis, primary liver tumors, cholestatic liver disease and acute 
liver failure (78). In this thesis no patients with acute liver failure are included. 
Before a transplantation is considered, all other meaningful treatment options 
should be explored. The timing of the decision to transplant involves weighing 
risk scenarios against each other. Decompensated liver cirrhosis is the most com-
mon indication for liver transplantation but other symptoms such as severe fatigue, 
malnutrition, sarcopenia and severe pruritus are important in the assessment and 
can be considered indications for liver transplantation. A liver transplantation 
evaluation is initiated when a patient’s health status is deemed to have no chance 
of improvement and the lifespan would be longer with a transplantation than 
without. The evaluation aims at investigating whether the patient is eligible for a 
13
liver transplantation and if there are any contraindications to undergo the surgery. 
Contraindications can be malignancies outside of the liver or large tumours inside 
of the liver, substance abuse, active infections, medical non-compliance, severe 
malnutrition/sarcopenia, or other diseases and condition affecting the ability to sur-
vive surgery, such as severe heart failure or respiratory illnesses. Different centres 
around the world have slightly different routines for which factors are evaluated. 
At Karolinska University hospital it is mandatory to have a nutritional assessment 
by a dietitian during the pre-transplant evaluation. The dietitian’s assessment aims 
at identifying risk factors regarding the nutritional status as well as performing 
nutritional interventions in order to optimise the nutritional status. 
A liver transplant evaluation normally takes around two weeks, and after under-
going all mandatory procedures the results are evaluated at a multi-disciplinary 
conference. The conference concludes whether or not the patient will be accepted 
and placed on the waiting list for a liver transplantation. Sometimes the result 
from the conference is that the patient needs additionally procedures for further 
investigation.
A challenge in liver transplantation is that it is mainly performed with grafts from 
deceased donors which means that the length of the waiting time is unpredictable. 
A patient under consideration for liver transplantation needs to receive care to 
eliminate the risk of developing contraindications for surgery during the waiting 
time, including optimising nutritional status to decrease the risk of complications 
during the waiting time and after liver transplantation (79). The recommendations 
involve, among others, to be physical active and maintain or improve current 
nutritional status and the dietitian is therefore an essential member of the health-
care team that cares for patients both before and after a liver transplantation. The 
waiting time is an uncertain time for the patient, and it is unpredictable how long 
each patient will wait. The length of the waiting time depends on the patient’s 
blood group, how many other patients are waiting at the same time and how sick 
each patient is as well as organ accessibility. Patients can be prioritised according 
to the principle “sickest first”, which means that the patient who is sickest will 
receive a liver transplantation first rather than the patient who has waited the long-
est. The waiting time can range from 1 day up to more than a year. The waiting 
time is usually 3-9 months at Karolinska University Hospital. 
Survival after liver transplantation has improved significantly to > 90% at one-year 
(80). The high survival rate is attributed to significant advances in immunosuppres-
sion therapy, surgical techniques and early detection of post-operative complications. 
After liver transplantation different complications can arise such as bile leakage, 
bleeding, rejection and infections. Infections is one of the most common causes 
for mortality within 6 months after liver transplantation while death from tumour 
recurrence or tumour de novo is more common late after liver transplantation (78).
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More than 7000 liver transplantations are performed annually in Europe (78). In 
Sweden, the first liver transplantation was performed in 1984 at the Huddinge 
Hospital. As of today, liver transplantation is performed in two centres in Sweden: 
Sahlgrenska University Hospital in Gothenburg and Karolinska University Hospital 
in Stockholm together perform 150-200 liver transplants annually (81). In the 
Nordic countries, the overall survival rate was 91% at 1 year and 71% at 10 years 
for patients transplanted between 2004-2013 (82). The one-year survival rate 
was 91.7% for patients transplanted between 2009-2017 at Karolinska University 
Hospital (unpublished data).  
2.5 Causes of malnutrition and sarcopenia in liver 
cirrhosis
Malnutrition in liver cirrhosis is caused both by an impaired food intake, malabsorp-
tion and altered macronutrient metabolism (83). Changes in the liver metabolism 
together with reduced food intake, nutrient malabsorption and altered energy con-
sumption (84) can negatively affect the nutritional status. A reduced food intake in 
patients with liver cirrhosis can be caused by different disease related symptoms. 
Common problems include loss of appetite, early satiety, nausea and functional 
dyspepsia. These symptoms can be assessed and quantified as NIS. Restrictive 
diets, for example salt-reduced diets, may cause a low energy intake. The cogni-
tive dysfunction in hepatic encephalopathy can involve difficulties to remember to 
eat or a reduced food intake. Iatrogenic fasting during hospitalisation can further 
reduce energy intake. Ascites, delayed gastric emptying and impaired gut motility 
can cause nausea and early satiety (85). Loss of appetite is frequently described 
by many patients and can be caused by other NIS or by an up-regulation of TNF-α 
and leptin (86). Altered taste can be caused by zinc deficiency (87) or by mouth 
dryness because of use of diuretic medicine. In patients with active substance 
abuse such as alcoholism there is a risk for poor and irregular dietary intake (88).
Malabsorption can occur in cirrhotic patients due to multiple factors such as por-
tosystemic shunting, intraluminal bile acid deficiency as a result of decreased bile 
production, chronic pancreatitis secondary to alcohol abuse or small intestinal 
bacterial overgrowth (89). In patients with portosystemic shunting, blood from 
the abdominal organs which should be drained by the portal vein into the liver 
is instead shunted to the systemic circulation. A part of the toxins, proteins and 
nutrients absorbed by the intestines bypass the liver and are shunted directly into 
the systemic circulation.
Alterations in glucose metabolism such as reduced glycogen storage, hyperinsu-
linemia, decreased glucose oxidation, glucose intolerance and diabetes mellitus can 
affect nutritional status and can potentially be treated with nutritional  interventions. 
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Patients with liver cirrhosis display increased gluconeogenesis, fat oxidation and 
protein catabolism after overnight fasting. Increased protein catabolism may develop 
even in early stages of liver cirrhosis and increases as the liver function deterio-
rates. Increased protein synthesis and concomitant increased protein degradation 
may explain the increased protein requirements in liver cirrhosis (84, 90, 91). 
2.6 The impact of nutritional status in chronic liver 
disease
Malnutrition, sarcopenia, obesity and sarcopenic obesity may worsen the prognosis 
of patients with liver cirrhosis and increase mortality (21, 92, 93). The first score 
that was developed in 1964 to classify surgical risk in patients with cirrhosis, by 
C.G. Child, included nutritional status as one variable in the score (94). Nutritional 
status was difficult to objectively evaluate and was deemed too subjective to include 
in the score and was therefore removed in the later versions of the Child-Pugh 
score (76). The MELD score does not take nutritional status into account (95), 
but there has been some effort recently to include muscle mass, and two different 
scores have been developed: Muscle-MELD score (96) and MELD-Sarcopenia 
(97). The MELD-sarcopenia score provides improved mortality estimation in cir-
rhosis by adding adds 10 points to the MELD score if a patient is suffering from 
sarcopenia. This demonstrates the prognostic importance of sarcopenia. The per-
formance of MELD-sarcopenia is better in patients with low MELD scores. The 
predictive values of these scores are yet to be validated in larger cohorts before 
they can be applied clinically, such as for liver transplantation organ allocation.
The prevalence of malnutrition differs between various countries, severity of liver 
disease and depends on which method is used for identifying malnutrition. The 
nutritional status and the severity of liver cirrhosis are closely linked. The risk 
of malnutrition increases as the liver disease progresses. One of the first studies 
using anthropometry to assess malnutrition in patients with liver disease showed 
that the prevalence increased from 20% in Child-Pugh A to over 60% in Child-
Pugh C (30). The prevalence of malnutrition in patients with chronic liver disease 
depends which method is used for nutritional assessment (30, 98, 99). Ferreira et 
al. (100) used different methods to assess the nutritional status of 159 patients on 
the waiting list for liver transplantation and highlight the disparities in prevalence 
of malnutrition depending on the method used: BMI 6.3 %, TSF 25.8%,  MAMC 
38.4%, SGA 74.7% and HGS 80.8%. In a study of 300 patients with advanced 
liver disease, more than 75% of the patients were malnourished and almost 40% 
were moderately to severely malnourished (99). 
Recent studies have focused on assessment of muscularity at the third lumbar verte-
brae (L3) transverse plane measured with CT. A retrospective review of CT images 
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of 142 patients (98) under evaluation for liver transplantation identified sarcopenia 
in 41% and found sarcopenia to be an independent predictor of mortality on the 
waiting list after adjustment for age and MELD score. The prevalence increased 
from 10% in Child-Pugh A to 34% in Child-Pugh B and 54% in Child-Pugh C. In 
a study of 234 patients with end-stage liver disease (101), more than 50% of those 
with BMI in the obese range were cachectic on CT body composition analysis. 
In a study of 366 living-donor liver transplanted patients, sarcopenia was defined 
as reduced skeletal muscle mass measured with CT and low muscle strength meas-
ured with hand grip strength. Patients with sarcopenia had greater incidence of 
postoperative complications of Clavien-Dindo grade IV and longer postoperative 
hospital stay (102). Sarcopenia was also a significant predictor of 6-month mortality. 
Severe muscle depletion is associated with an increased length of stay after liver 
transplantation (103). Sarcopenia has been shown to impair the prognosis in liver 
cirrhosis (23). For patients undergoing liver transplantation, malnutrition has been 
reported to affect length of stay (LOS), rate of serious infections and mortality (7, 
98). Malnutrition is associated with mortality but also the risk of developing HE 
and ascites (104, 105). In one of the few randomised trials to assess nutritional 
therapy in patients with minimal hepatic encephalopathy, Maharshi et al found that 
patients achieving the recommended energy- and protein intake were less likely 
to develop overt HE (106).
The prevalence of sarcopenia depends on country, age, gender distribution and 
severity of liver disease of the study population. Studies involving participants 
with a higher proportion of patients with more severe liver disease tend to report a 
higher frequency of sarcopenia. Table 2 highlights these disparities in prevalence 
of sarcopenia and muscle mass depletion in different studies. 
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Table 2. Prevalence of sarcopenia or muscle mass depletion in different studies 
investigating skeletal muscle mass index with computed tomography
Reference Country N Year Male Age MELD
Child-
Pugh 
B/C
Sarcopenia/
muscle mass 
depletion
Meza-Junco 
et al (107)
Canada 116 * 85% 58 9 47% 30%
Wang et al 
(108)
USA 292 2011-
2014
66% 61 15 73% 38%
Montano-
Loza et al 
(21)
Canada 678 2000-
2013
67% 56-58 13-16 79-91% 43%
Wells et al 
(109)
New 
Zealand
107 2004-
2010
71% 54 12 66% 43-53%
Hanai et al 
(23)
Japan 130 2004-
2012
58% 66 11 74% 68%
DiMartini 
(110)
USA 338 2005-
2008
66% 55 20 * 68%
Giusto et al 
(35)
Italy 59 2011-
2013
78% 59 13.1-
13.5
66% 76%
*Information not available in the published article. The column “Year” refers to time period when 
the data collection was performed, not the year when the study was published.
Obesity has adverse effects on health in many situations, also in chronic liver 
disease where obesity can affect progression of the disease. Obesity is considered 
one of the major risks for developing non-alcoholic fatty liver disease (NAFLD), 
and NAFLD represents the hepatic part of the metabolic syndrome (111). Obesity 
is also considered an independent risk factor for fibrosis progression (112). In 
patients with Hepatitis C, the risk of progression to liver cirrhosis or decompensa-
tion has been shown to increase by 14% for each increase in BMI quartile (113). 
An intervention study with diet and exercise to lose weight in obese patients with 
compensated cirrhosis, showed that portal pressure and body weight was reduced 
after a 16 week long program (114). The results from this study suggest that obe-
sity promotes portal hypertension. In context with the growing understanding of 
the role of obesity in liver disease it is important to acknowledge that obesity does 
not rule out malnutrition or sarcopenia. Sarcopenic obesity is prevalent in patients 
before and after liver transplantation (21, 115, 116) and patients with sarcopenic 
obesity have worse survival rate than patients with sarcopenia alone (21). Patients 
with sarcopenic obesity have a risk of adverse outcomes both from obesity and 
from low muscle mass, the risk can be higher than the risk induced by each of the 
two conditions alone.
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2.7 Quality of life in chronic liver disease
Quality of life is a concept that encompasses both positive and negative aspects 
of life. Health-related quality of life (HRQOL) “is a subjective measure depend-
ing on an individual’s perception of the impact of disease and/or treatment on 
their health status” (117). Patients with chronic liver disease have been reported 
to have an impaired HRQOL (118, 119). Low HRQOL has been shown to be 
correlated with grade of liver disease (120, 121). Complications of liver disease 
such as ascites and hepatic encephalopathy have a negative impact on quality of 
life (122-124). Ascites and hepatic encephalopathy may also increase the risk of 
developing eating difficulties. These complications can to some extent be treated 
with nutritional interventions (125, 126) and HRQOL can potentially improve if 
symptoms are treated. HRQOL can be studied with questionnaires such as the 
Medical Outcomes Study Short Form-36 or with disease-specific questionnaires 
such as the Chronic Liver Disease Questionnaire (CLDQ) (127).
A study of 1175 patients with chronic liver disease in the Netherlands found HRQOL 
in chronic liver patients to be determined by disease severity, joint pain, depression, 
decreased appetite and fatigue (118). Another study of patients with liver disease found 
the presence of gastrointestinal symptoms such as reflux, abdominal pain, constipation, 
indigestion and diarrhea to be correlated with weight loss and poor quality of life (62).
Some studies have found conflicting results. Older age and measures of disease 
severity were associated with poorer HRQOL and family income was positively 
correlated with CLDQ (120). CLDQ scores were however not related to age, gender, 
or level of education in another study (128). Two studies found HRQOL scores 
to be decreased with worsening of liver function (119, 122) while another study 
found psychiatric comorbidity and active medical comorbidity, but not severity of 
the liver disease according to the Child-Pugh score, to determine reduced HRQOL 
in patients with chronic liver diseases (129). In a Danish prospective study of 92 
patients with chronic liver disease, Child-Pugh score, non-alcoholic etiology of 
cirrhosis, and BMI were predictors of poor HRQOL. The BMI predicted poor 
HRQOL independently of the presence of ascites (130). 
Some authors have studied the impact of malnutrition on HRQOL. In an Indian 
study by Panagaria et al, the severity of liver disease was negatively correlated 
with quality of life and energy intake was positively correlated with quality of 
life (131). In a recent study of 127 patients with liver cirrhosis, 59.8% reported 
a reduced HRQOL and a strong association with malnutrition was found (132).
The impact of nutritional status on quality of life has also been reported in other groups 
of patients. In a systematic review, 24 out of 26 articles showed that a good nutrition 
status is also associated with a higher quality of life in patients with cancer (133). 
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3 AIMS
The overall aim of this thesis was to increase the knowledge of nutritional assess-
ment in chronic liver disease before and after liver transplantation. The specific 
aims of this thesis were:
• To study the prevalence of malnutrition among patients listed for liver 
transplantation and to investigate associations between body composition 
parameters measured with DXA and outcome after liver transplantation. 
(Study I)
• To perform inter-method comparisons between three measures of muscle 
mass in patients eligible for liver transplantation: fat free mass index 
(FFMI) measured by DXA, appendicular skeletal muscle mass (ASMI) 
measured by DXA and skeletal muscle mass index (SMI) measured by 
CT. (Study II)
• To assess the prevalence and severity of NIS in patients with chronic 
liver disease under evaluation for liver transplantation and to explore 
associations between NIS, malnutrition and HRQOL. (Study III)
• To compare measured REE with predicted REE calculated by HB and 
with energy requirements determined by the fixed factors (25, 30 and 35 
kcal/kg/day), to identify clinical factors associated with REE early after 
liver transplantation, and to explore whether data from our cohort could 
enable constructing an equation that predicts energy requirement better 
than the HB. (Study IV) 
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4 MATERIAL AND METHODS
4.1 A summary of the studies
An overview of the study design of each study included in the thesis is describe 
in Table 3.
Table 3. An overview of the studies included in the thesis
Study I II III IV
Design Retrospective
Cohort
Retrospective
Cohort 
Cross-sectional Retrospective 
Cohort
Study 
population
Liver transplanted Liver transplanted Undergoing liver 
transplantation 
evaluation 
Liver transplanted
Data source 
(s)
DXA, Medical 
records, local 
transplant registry
DXA, CT, Medical 
records, local 
transplant registry
Questionnaires, 
DXA, 
Anthropometry, 
Medical records
IC, Medical 
records, local 
transplant registry
Study period 2009-2012 2009-2012 2016-2018 2011-2018
Inclusion 
criteria
Chronic liver dis-
ease, ≥ 19 years 
of age, DXA 
performed at 
Karolinska 
Chronic liver dis-
ease, ≥ 19 years 
of age, had a 
DXA and CT scan 
within 30-d 
Chronic liver dis-
ease, ≥ 18 years 
of age
LT with a graft 
from deceased 
donor, ≥ 18 years 
of age, IC done 
in within 30-d 
postop
Exclusion 
criteria
Previous LT, 
multiorgan 
transplantation
Previous LT, mul-
tiorgan or hyper 
urgent transplan-
tation, non-cir-
rhotic patients.
Age <18 
years, inabil-
ity to fill in the 
questionnaires
Multiorgan or 
hyper urgent 
transplantation 
Main factors 
analysed
Prevalence of 
muscle mass 
depletion and 
association with 
outcomes post-LT
Comparison of 
DXA and CT 
in measuring 
muscle mass 
depletion
Frequency of 
nutrition impact 
symptoms and 
association with 
malnutrition and 
HRQOL
mREE compared 
with HB and fixed 
factors, asso-
ciations with pre- 
and postoperative 
factors
Statistical 
analysis
Chi-square or 
Fisher test, 
Mann-Whitney, 
logistic and 
multiple linear 
regression.
Chi-square or 
Fisher test, One-
way analysis 
of variance or 
Mann-Whitney, 
Pearson correla-
tion coefficient.
Chi-square, 
t-test, median 
regression, mul-
tinomial logistic 
regression.
Lin’s concord-
ance correla-
tion coefficient, 
Bland-Altman 
plots, Chi-square, 
Kruskal- Wallis 
test, multiple 
linear regres-
sion, stepwise 
regression 
DXA; dual-energy x-ray absorptiometry, LT; liver transplantation, CT; computed tomography, 
HB; Harris & Benedict equation, HRQOL; health-related quality of life, IC; indirect calorimetry, 
mREE; measured resting energy expenditure, REE; resting energy expenditure, TEE; total 
energy expenditure
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4.1.1 Inclusion and exclusion
This thesis includes studies on patients undergoing liver transplantation evalua-
tion Study I, II, III) and liver transplantation (Study I, IV) at Karolinska University 
Hospital in Stockholm, Sweden. The four studies in this thesis are based on differ-
ent study cohorts generated by different methods, and the populations are partly 
overlapping (Figure 4).
Figure 4. Overview of study periods
Data on consecutive liver transplantations between 2009 and 2012 were retrospec-
tively reviewed for Study I and II. In total 228 liver transplantations were performed 
on adult patients during this time period. Patients with non-chronic liver disease, 
previous liver transplantation or multi-organ transplantation were excluded as 
well as patients who did not have a DXA scan or a formal nutrition assessment 
performed at Karolinska University hospital. In total 109 patients fulfilled the 
inclusion criteria: age above 18, chronic liver disease and had a DXA-scan per-
formed and consisted the cohort for Study I. Patients from the same cohort which 
had both a DXA and a CT scan performed within 30-days during the pre-transplant 
evaluation was included in Study II.
Adult patients with chronic liver disease under evaluation for liver transplanta-
tion during the time period February 2016 until February 2018 were invited to 
participate in Study III. In total 133 patients accepted participation and signed the 
study informed consent form. Exclusion criteria were age < 18 years, inability to 
fill in the questionnaires for example because of language difficulties or severe 
hepatic encephalopathy.
Study IV was a retrospective analysis of patients who underwent liver transplan-
tation between 2011-2018. Inclusion criteria were age ≥ 18 years at time of liver 
transplantation, liver transplantation with a graft from a deceased donor and had 
an indirect calorimetry performed within 30 days after a liver transplantation. 
Exclusion criteria was multi-organ transplantation or transplantation because of 
acute liver failure.
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4.2 Data sources
Figure 5 presents an overview of when different data was collected in the four 
studies included in this thesis.
Figure 5. Overview of the four studies and data collection time points
ASMI; appendicular skeletal muscle mass index, CLDQ; chronic liver disease questionnaire, CT; 
computed tomography, DXA; dual-energy x-ray absorptiometry, DRAQ; disease related appetite 
questionnaire, ESQ; eating symptom questionnaire, FFMI; fat-free mass index, FMI: fat-mass 
index, GLIM; The Global Leadership Initiative on Malnutrition, HRQOL; health-related quality 
of life, IC; indirect calorimetry, LT; liver transplantation, REE; resting energy expenditure, SMI; 
skeletal muscle mass index
4.2.1 Medical characteristics and post-transplant outcome 
In all four studies information was collected from medical charts and the local 
liver transplant registry Ekvator. Information was double-checked in the chart 
and in the registry to minimise the risk of error and missing data. The Child-Pugh 
and MELD scores were collected to grade severity of liver disease. Allocation of 
organ at Karolinska University Hospital is based on Child-Pugh score in combina-
tion with comorbidity and performance status and not primarily MELD based. No 
extra MELD points are given for e.g. hepatocellular carcinoma (HCC). Infections 
and LOS after liver transplantation was studied in Study I. Severe infections were 
defined as systemic or requiring intravenous or prolonged courses of antimicrobi-
als within 30 days of liver transplantation. LOS at the transplant center as well as 
the ICU was collected. Surgical complications from liver transplantation up until 
3 months postoperatively were classified according to the Clavien-Dindo clas-
sification (134) in Study IV. Clavien-Dindo grade complications from none to V. 
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Grade III-IV are considered more severe complications where grade III requires 
surgical, endoscopic or radiological intervention, grade IV is life-threatening 
complication and grade V is death of patient. 
4.2.2 Body composition
A DXA-scan to screen for osteoporosis is performed during the pre-transplant evalu-
ation for all patients referred to Karolinska University Hospital. In some regions 
of Sweden, DXA is performed at the referring hospital, and those patients were 
not included in Study I-III. The DXA scans performed at Karolinska University 
hospital were performed with a fan-beam DXA (GE Lunar iDXA; system number 
ME +200030; GE Lunar Corp., Madison, WI, USA). The reported precision for 
the DXA machine used in Study I-III is high with coefficient of variations of 0.5% 
for lean tissue mass and 0.82% for total fat mass (135).
Data on fat mass, lean soft tissue and bone minerals were collected from the DXA 
scans for Study I-II. Fat mass was adjusted for height to calculate fat mass index 
(FMI). Lean soft tissue together with bone minerals constitute fat free mass which 
was also adjusted for height to calculate FFMI. For Study II-III ASMI was calcu-
lated from appendicular lean soft tissue mass (kg) divided by squared body height.
CT-scans performed during the pre-transplant evaluation were used to measure 
body composition in Study II. Each pixel from the scans attenuation is reported 
in Hounsfield units (HU). HU thresholds used in the study was -150 to -30 for 
fat (136) and -29 to +150 for muscle (137). The overlapping area -29 to + 30 was 
quantified separately together with average attenuation to quantify fat infiltration 
in the muscle (138). The tube voltage for CT was 100 to 120 kV. A transverse 
single 5-mm-thick image from the middle of the L3 vertebra was extracted from 
each scan. The software Image J 1.50c from the National Institutes of Health, 
USA, (139) was used for segmentation. The psoas and paraspinal muscles (erec-
tor spinae, quadratus lumborum), and the abdominal wall muscles (transversus 
abdominis, external and internal obliques, rectus abdominus) were segmented as 
well as visceral and subcutaneous adipose tissues at the L3 level.
4.2.3 Resting energy expenditure
REE was extracted from indirect calorimetry measurement performed for clinical 
reasons. REE was measured by indirect calorimetry, using Fitmate® (COSMED, 
Rome, Italy), previously validated for REE measurements in adults (140, 141). The 
patients were rested in a supine position for more than 30 minutes and were asked 
to remain motionless and awake during the test. Measurements were performed 
after overnight fast (>8 hours of fasting), or 4 hours of fasting. The device was 
automatically calibrated before each measurement. The volume of inspired oxygen 
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was collected using a face mask with integrated bacterial filter. The exhaled gas 
was collected over 20 minutes, and the gas collected over the first five minutes was 
discarded. The mean volume of inspired oxygen per minute was used to calculate 
the REE according to the Weir (142) formula. Hypermetabolism was defined as a 
measured REE (mREE) ≥120% of the predicted value from HB; normometabo-
lism, as a mREE within 80-119% of the predicted value, and hypometabolism, as 
a mREE < 80% of the predicted value (143). Total energy expenditure (TEE) was 
calculated as mREE x physical activity level 1.2 (144-146) to enable comparisons 
with the fixed factors. 
4.2.4 Questionnaires
The chronic liver disease questionnaire (CLDQ) was developed in USA twenty 
years ago (147), and has been extensively used in liver research. In study III, a 
validated Swedish version was used (148). The CLDQ includes 29 questions graded 
on a seven-point scale from 1 (all the time) to 7 (none of the time). The questions 
comprise six domains; abdominal symptoms, fatigue, systemic symptoms, activ-
ity, emotional functioning and worry. The questionnaire gives domain scores as 
well as a total CLDQ score.
Two different questionnaires were used to assess the presence of NIS: The Eating 
Symptom Questionnaire (ESQ) and the Disease-Related Appetite Questionnaire 
(DRAQ). The ESQ and DRAQ were developed by means of dietitian led focus 
groups and patient interviews with the purpose to investigate NIS in patients at 
risk of developing malnutrition or patients suffering from malnutrition (70). The 
questionnaires have previously been used to investigate NIS in patients with dif-
ferent cancers (149) and gastrointestinal diseases (68). No validation study has 
been done since there is no gold standard for investigating NIS. The ESQ encom-
passes a list of symptoms that could affect eating and/or appetite and whether 
any of these symptoms was experienced during the last two weeks on a five-level 
Likert scale, from no trouble at all to severe symptoms. The ESQ includes an open 
question at the end of the questionnaire where the respondent can describe any 
additional symptoms not included in the list. The DRAQ has a different design 
and consists of 11 questions relating to appetite, hunger and other symptoms that 
may affect eating. 
A general population of Swedes between 18-74 years of age were also asked to 
fill in ESQ and DRAQ to see if the prevalence of NIS were different between the 
cohort of patients with chronic liver disease and the general population. Two of 
the questions from DRAQ were removed for the general population (“Compared 
with when I was healthy food tastes…” and “How long has the disease affected 
your appetite?”). Consumer Intelligence, a company that provides target groups for 
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use in connection with internet-based research sent out questionnaires to approxi-
mately 3950 men and women between the ages of 18-80 which resulted in com-
plete questionnaires from 506 individuals nationally representative according to 
gender, age and geographical region. This data was not included in the published 
paper regarding nutrition impact symptoms (Study III), although some results are 
presented in the result section of this thesis.
4.3 Defining malnutrition and muscle mass depletion
Different methods to define malnutrition were used in study I and study III. In study 
I, cut-offs for FMI and FFMI were <5th percentile according to age and gender 
from a reference population (150) were used to diagnose malnutrition as well as 
assessment performed by a dietitian. A retrospective review was performed of the 
nutritional assessments performed by dietitians during the pre-transplant evalu-
ation. Between 2009-2012 the dietitians as Karolinska University Hospital went 
through a process of structuring their assessment according to the Nutrition Care 
Process (1). The definition of malnutrition changed slightly during the study period 
and in some cases it was not clear during which time period the patient had lost 
weight. For that reason, malnutrition was defined as weight loss > 10% (unspeci-
fied time period) in combination with eating difficulties or BMI <20. In study II 
muscle mass depletion was defined according to the following cut-offs: age and 
sex adjusted FFMI indices <10th percentile (150), ASMI 7.59 kg/m2 for men and 
5.47 kg/m2 for women (151). SMI cut-offs for muscle depletion were <43 cm2/m2 
for men with BMI <25 kg/m2 and <53 cm2/m2 for BMI >25 kg/m2 and <41 cm2/m2 
for women in all BMI ranges (52). SGA was used to diagnose malnutrition dur-
ing the time period 2016-2018 (6) and was presented for descriptive purposes in 
Study III. The GLIM criteria published in 2018 (15) were retrospectively assessed 
to diagnose malnutrition in Study III and used for all the statistical analysis. The 
cut-offs used for reduced muscle mass according to ASMI in Study III were: 7 kg/
m2 for men and 6 kg/m2 for women (152). 
26
4.4 Statistical analysis
The statistical test that were used in Study I-IV are summarised in Table 3. Descriptive 
statistics were used for categorical (number and percentage) and continuous vari-
ables (mean and standard deviation or median and inter-quartile range (IQR) 
according to distribution). A p-value <0.05 was considered statistically significant.
4.4.1 Study I
Univariate analysis was done with Chi-square or Fisher’s exact test for categori-
cal data, and Mann–Whitney for continuous variables with skewed distribution. 
A logistic regression model was fitted for the dichotomous outcome variable of 
post-operative infections up to one month after liver transplantation. The model 
adjusted for age, sex, body composition (measured as FMI or FFMI), indication 
for liver transplantation, causes of end-stage liver disease, weight loss, nutritional 
assessment by dietitian, time on the waiting list, MELD score at the time of liver 
transplantation, perioperative bleeding, need for dialysis, duration of mechanical 
ventilation, and length of stay in the ICU and hospital. Model fitness was assessed 
with the Hosmer-Lemeshow test.
Multiple linear regression analyses, with the length of stay in the ICU in the 
first model and duration of hospitalisation in the second as outcome variables, 
were constructed separately. The models adjusted for age, sex, body composition 
(measured as FMI or FFMI), indication for transplantation, causes of end-stage 
liver disease, weight loss, nutritional assessment by dietitian, time on the wait-
ing list, MELD score at the time of liver transplantation, post-operative bleeding, 
need for dialysis, and duration of mechanical ventilation. In the model with the 
duration of hospitalisation, adjustments for the length of stay in the ICU and post-
operative infections up to 1 month were also included. In selecting variables for 
the multivariate analysis, we used a combination of predefined predictors based 
on literature search, and any significant variable in the univariate analyses. Thus, 
we did not only include significant predictors from the univariate analyses in the 
final multivariate model, as such an approach might wrongly reject potentially 
important variables (153). Testing for influential cases and outliers in regression 
models was also done, and such cases were excluded from the primary analysis. 
A further sensitivity analysis was then done with the inclusion of these outliers to 
check for changes in the significance level of predictors. Statistical analyses were 
performed with the SAS® software version 9.4 (Cary, NC).
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4.4.2 Study II
Intra-class correlation (ICC) scores between two independent raters were cal-
culated for 20 of the patients. Data were tested for normal distribution with the 
Shapiro-Wilks test. For categorical variables, the Chi-square test or the Fisher test 
was used for group comparisons. To detect any differences between patients with 
and without muscle mass depletion, one-way analysis of variance was used for 
variables of symmetric distribution and the Mann-Whitney test for variables of 
asymmetric distribution. Correlations between continuous variables were assessed 
using Pearson correlation coefficients. The software used for the analysis were 
SPSS version 19 (IBM, Armonk, NY, USA) and SAS (SAS Institute, Cary, NC, 
USA) for Windows.
4.4.3 Study III
To test for differences in distributions, Chi-square test was used for categorical 
data and t-test for continuous variables. Median regression was used to assess the 
association between CLDQ and malnutrition. Multinomial logistic regression was 
used to analyse which NIS were predictors of malnutrition according to GLIM, 
after adjusting for sex, Child-Pugh class and ascites. The statistical analyses were 
performed with SPSS version 25 (IBM, New York, NY, USA) and Stata version 
15 (StataCorp, College Station, TX, USA).
4.4.4 Study IV
Agreement between mREE and predicted REE and fixed factors were assessed 
with Lin’s concordance correlation coefficient (CCC) that combines measures of 
precision and accuracy, Bland-Altman plots, and 95% confidence intervals (CI). 
Differences in distribution between groups of hypo-, normo- and hypermetabolism 
were tested with Kruskal-Wallis test for continuous variables and Chi-square test 
for categorical data. 
A multiple linear regression with robust standard errors was performed using 
the mREE as a dependent variable to test for associations between variables and 
mREE. Robust standard errors were used to avoid homoscedasticity. 
A new predictive equation was constructed for REE using predictive coefficients 
devised from using stepwise regression analysis of variables that were significantly 
associated with mREE in the multiple linear regression. The agreement of this 
new devised formula for predicting REE with mREE was tested with CCC. The 
statistical analyses were performed with SPSS version 25 (IBM, New York, NY, 
USA) and Stata version 15 (StataCorp, College Station, TX, USA).
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5 ETHICAL CONSIDERATIONS
All studies were conducted in accordance with the Declaration of Helsinki. The 
studies within this thesis were approved by the Regional Ethical Review board in 
Stockholm, Sweden (Study I and II: 2012/2018-31/1, Study III: 2015/2045-31/2 
and Study IV: 2017/830-31/1, 2019-03646). Informed written consent was signed 
by all participants in Study III. 
The Declaration of Helsinki was developed to protect human subjects rights and 
health. The four principals of medical ethics (to do good, respect for autonomy, 
do no harm, be just) have been considered in this thesis (154). Research should 
be conducted for the benefit of others. The purpose of this thesis is to do good: 
to gain knowledge on how to improve nutritional assessment in patients under-
going liver transplantation in order to identify who needs treatment. The results 
can be beneficial for future patients undergoing liver transplantation. The second 
principle, respect for autonomy, is taken into consideration during anonymisa-
tion of the data. All data was coded, and all analyses were performed on a group 
level, thus minimising the risk of any individual being identified. In Study III, 
informed consent was collected.  In Study III it is important to acknowledge that 
a pre transplant evaluation is an exposed position for a patient, where the patient 
is evaluated if they will be allowed to receive a liver transplantation. Information 
about the study was sent to the patient before the visit to the dietitian. When the 
nutritional assessment was finished the patient was asked about study participa-
tion. It was emphasised that participation was voluntary and could be stopped at 
any point without explanation. The study was constructed in a way to not cause 
any harm except for the time spent on filling out the questionnaires. There was no 
direct benefit for those who participated. The potential privacy violation that can 
arise from answering questions about symptoms and quality of life was handled 
by the patient having the right to refuse or abort participation in the study at any 
time and by anonymisation of data during analysis. All patients under evaluation 
for liver transplantation during the study period were asked for participation. The 
study however excluded patients who did not understand Swedish or suffered 
from severe encephalopathy. The ability to independently make decisions about 
participation is reduced when an interpreter needs to be used to translate informa-
tion or when the level of consciousness is reduced. The principle of justice could 
be influenced since all persons should be treated equally and some patients were 
not asked to participate because of the above reasons. 
The studies in this thesis are not experimental and therefore fulfil the principle of 
not harming the participants. 
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6 RESULTS
6.1 Study participants
A selection of patient characteristics in the different studies are shown in Table 4.
Table 4. Overview of clinical characteristics in Study I-IV
Study I II III IV
Number of patients 106 53 133 143
Male, number (%) 68 (64) 37 (70) 97 (73) 106 (74)
Age, median (IQR) 55 (16) 57 (16) 59 (19) 51 (19)
MELD, median (IQR) 13 (7) 11 (8) 12 (7) 12 (9) *
Child-Pugh score, n (%)
A
B
C
32 (30)
41 (39)
33 (31)
27 (51)
14 (26)
12 (23)
46 (35)
64 (48)
23 (17)
n/a
Ascites, n (%) 44 (42) 19 (36) 50 (38) 47 (36)**
Hepatocellular carcinoma, n (%) 36 (34) 28 (53) 51 (38) 39 (27)
Cause of liver disease, n (%)
Autoimmune
Viral with/without alcohol
Alcohol
NASH***
Other
33 (31)
50 (47)
10 (9)
x
13 (12)
16 (30)
27 (51)
4 (8)
x
6 (11)
49 (37)
30 (23)
28 (21)
14 (11)
12 (9)
57 (40)
34 (24)
21 (15)
x
31 (22)
IQR; interquartile range, MELD; model for end stage liver disease, NASH; non-alcoholic steato-
hepatitis *MELD at day before liver transplantation, **14 missing data, *** Patients with NASH 
were included in the group “other” in Study I, II and IV. Information on ascites and hepatocel-
lular carcinoma was collected on the day before liver transplantation for Study IV, for Study I-III 
the data refers to the present of this condition during the pre-transplant evaluation.
6.2 Nutritional status
Several techniques to study malnutrition and body composition were used in this 
thesis. The prevalence of malnutrition was 2-20% in Study I and 32% in Study III. 
Muscle mass depletion varied between 30-40% in Study II. Table 5 describes the 
different cut-offs that were used for muscle mass depletion in the different studies. 
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Table 5. Prevalence of muscle mass depletion and cut-offs used in Study I-III
Study I Study II Study III
Cut-off Below cut-off Cut-off Below cut-off Cut-off  Below cut-off
FMI Age 
and sex 
adjusted 
< 5th 
percentile
All 9%
M 6%
F 16%
FFMI Age 
and sex 
adjusted 
< 5th 
percentile
All 15%
M 20%
F 5%
Age and sex 
adjusted 
< 10th 
percentile
All 30%
M 38%
F 13%
ASMI M 
<7.59 kg/m2 
F 
<5.47 kg/m2
All 39%
M 40%
F 38%
M
<7 kg/m2 
F 
<6 kg/m2
All 23%
M 20%
F 30%
SMI M
<43 cm2/m2 
for BMI <25 
kg/m2 and 
<53 cm2/m2 
for BMI >25 
kg/m2 
F
<41 cm2/m2 
in all BMI 
ranges
All 40%
M 27%
F 69%
FMI; fat mass index, FFMI; fat-free mass index, ASMI; appendicular skeletal muscle mass 
index, SMI; skeletal muscle mass index, M; male, F; female.
Study I and II: Coin et al. Fat-free mass and fat mass reference values by dual-energy X-ray 
absorptiometry (DEXA) in a 20-80 year-old Italian population (150)
Study II: Martin et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a pow-
erful prognostic factor, independent of body mass index (52)
Study III: Cruz-Jentoft et al. Sarcopenia: revised European consensus on definition and diagno-
sis (17)
The median BMI was 25.1 kg/m² in Study I and II. In Study III and IV, the median 
BMI was 26 kg/m². The majority of patients in all four studies had a BMI in the 
range between normal weight and overweight and 15-20% were obese (Figure 6).
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Figure 6. Percentage of patients classified within different BMI-groups across the 
studies
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BMI; body mass index. BMI at time of pre-transplant evaluation for Study I, II, III. BMI 
at pre-transplant day 0 for Study IV.
Weight loss during the last six months was found in 45% of the patients in Study 
I, with 17% reporting ≥ 5% weight loss and 20% had lost ≥ 10% of their weight. 
In Study III, 47% of the participants reported some degree of weight loss, where 
14% had lost ≥ 5% and 6% had lost ≥ 10% of their body weight. 
6.3 Study I
Hundred and nine patients who underwent liver transplantation during the study 
period 2009-2012 had a DXA-measurement performed during the pre-transplant 
evaluation and were included in the study. Three DXA scans were excluded because 
of ambiguous results and the study cohort therefore consisted of 106 patients. The 
prevalence of malnutrition depended on assessment method. Body composition 
measured by DXA during the pre-transplant evaluation was found to provide 
valuable information, FFMI was associated early post-transplant infections. There 
were 64% men, and median age was 55 years. The most common aetiologies for 
end-stage liver disease were viral hepatitis (35%), autoimmune diseases (31%) 
and alcoholic liver disease (22%). At the day before the transplant, the median 
Child-Pugh score was 9 (IQR 4) and 42% had ascites.
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There were large gender differences in body composition. In total 15% of the 
population had low FFMI according to the age and gender adjusted cut-offs that 
were used. Low FFMI was present in 20% of the men, and in 5% of the women. 
The opposite distribution was found for FMI, with 9% of the entire population 
presenting with low values. Six percent of the men had low FMI and 16% of the 
women. If the cut-offs previously suggested by ESPEN (155) were to be applied 
for FFMI, the prevalence would instead be 16 % with a low FFMI, with 8 (21%) 
women and 9 (13%) men. Figure 7 illustrates the relationship between FFMI and 
BMI according to gender (not included in the published paper). 
Figure 7. Scatterplot FFMI/BMI
BMI; body mass index, FFMI; fat-free mass index
The nutritional assessment performed by dietitians identified 57% at no risk of 
malnutrition, 39% at risk of malnutrition and 5% as malnourished.  When com-
paring the nutritional assessment with FFMI and FMI, there were no significant 
difference in FFMI (p=0.142) between the groups. FMI was significantly differ-
ent in the patients classified as at risk of malnutrition or malnourished (p=0.007).
Thirty seven percent of the patients included in the study developed severe infec-
tions within the first 30 postoperative days. In the multivariate analysis with 
logistic regression, body composition (FFMI) was significantly associated with 
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post-operative infection when measured with FFMI (odds ratio (OR) = 0.67; 95% 
confidence interval (CI) = 0.45–0.99), in contrast FMI was not significantly asso-
ciated (OR = 0.85; 95% CI = 0.70–1.02). Longer length of stay in hospital was 
associated with a higher risk of infection (OR = 1.2; 95% CI = 1.1–1.3), whereas 
increasing age was associated with a lower risk of post-operative infection (OR 
= 0.91; 95% CI = 0.85–0.99).
6.4 Study II
Fifty-three patients who underwent a liver transplantation between 2009-2012 had a 
CT and DXA measurements within a 30-day period during the pre-transplant evalu-
ation and were included in the study. We found that appendicular skeletal muscle 
mass index measured by DXA (ASMIDXA) and skeletal mass index measured by 
computed tomography (SMICT) provided similar results when assessing the pres-
ence of muscle mass depletion in patients with chronic liver disease. Fat-free mass 
index measured with DXA (FFMIDXA) can be falsely high in patients with ascites. 
There were no significant association between SMICT and liver function measured 
by Child-Pugh score (p = 0.366), aetiology of liver disease (p = 0.57) or with the 
presence of HCC (p = 0.70).
Muscle depletion varied among methods and gender. FFMIDXA, ASMIDXA, and 
SMICT were relatively consistent among men (FFMIDXA 38%, ASMIDXA 40%, and 
SMICT 27%). There were large discrepancies for women between methods (FFMIDXA 
13%, ASMIDXA 38%, and SMICT 69%). 
During the pre-transplant evaluation, thirty-one (59%) patients had a measurement 
of hand grip strength by a hand grip dynamometer (not in the published paper). 
Eight (26%) patients showed a significant reduction in muscle strength (HGS≤10th 
percentile (156)). Of the patients who had HGS measured, sarcopenia (low muscle 
strength and low muscle mass) was present in 2 (7%) FFMIDXA, 5 (16%) ASMIDXA 
and 3 (10%) SMICT. A Pearson correlation test was performed between HGS and 
muscle mass measurements. ASMIDXA and HGS showed the strongest correlation 
(r=0.77, p =<0.001), a strong correlation was also found between HGS and SMICT 
(r=0.68, p =<0.001).  HGS did not correlate with FFMIDXA (r=0.25, p =0.180).
There were no differences in measured visceral or subcutaneous fat in mus-
cle depleted patients according to SMICT compared to patients with no muscle 
depletion. ASMIDXA, but none of the other body composition parameters, showed 
statistically significant difference between the patients with and without muscle 
depletion (Table 6).
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Table 6. Body composition characteristics during the pre-transplant evaluation 
according the presence or absence of muscle depletion measured by SMICT
All 
(n= 53)
Muscle 
depletion 
(n= 21)
No muscle 
depletion 
(n=32)
p
Body composition  
Weight 75.2 (20.5) 67.2 (21) 78.6 (17) 0.186
Height 173 (17) 171 (18) 172.5 (10) 0.507
BMI, kg/m² 25.1 (5.3) 24.4 (6) 25.4 (6) 0.184
Obese BMI ≥ 30, n (%) 8 (15) 2 (10) 6 (19)  0.426
Fat  
Visceral fat, cm² 125 (69.3) 120 (140) 118 (79) 0.891
Subcutaneous fat, cm² 298.1 (137.1) 307 (202) 311 (152) 0.963
Adipose tissue surface area at L3 (cm²) * 423.1 (193.4) 459 (305) 406 (209) 0.731
Adipose tissue index* 143 (62) 138 (91) 145 (84) 0.494
FMI DXA 7.2 (3,6) 7.7 (6) 6.8 (4) 0.651
Muscles  
ASMI DXA ** 7.4 (1.5) 6.5 (2.1) 8.0 (1.4) <0.001
FFMI DXA 18.2 (2.3) 17.1 (3.5) 18.4 (3.3) 0.144
Skeletal muscle area L3 (cm²) 155.5 (31.5) 126.2 (54.6) 170.8 (30.7) <0.001
SMI (mean + SD) 49.6 (10.6) 37.8 (5.6) 54.8 (12.2) <0.001
BMI; body mass index, FMI; fat mass index, DXA; dual-energy x-ray absorptiometry, ASMI; 
appendicular skeletal muscle mass index, SMI; skeletal muscle mass index. Median and inter-
quartile range unless otherwise stated. T-test with equal variances not assumed. *Missing data 
5 patients, ** Missing data 2 patients
We found a strong inter-method correlation between SMICT and ASMIDXA, and the 
presence of ascites did not influence the correlation between these measures. FFMI 
by DXA was not correlated with SMI or ASMI in patients with ascites. Figure 8 
shows scatterplots of the relationship between the different measurements accord-
ing to presences or absence of ascites.
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Figure 8. Scatterplot of the relationship between SMICT, FFMIDXA, and ASMIDXA 
   
ASMI; appendicular skeletal muscle mass index, CT; computed tomography, DXA; dual-energy 
x-ray absorptiometry, FFMI; fat-free mass index, SMI; skeletal muscle mass index
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6.5 Study III
In total, 133 adult patients with chronic liver disease under evaluation for liver 
transplantation participated in the study.  We found a high prevalence of NIS in 
patients with chronic liver disease and strong correlations between the frequency 
of NIS, HRQOL and malnutrition. 
Among the included patients, 35% were Child-Pugh A, 48% Child-Pugh B and 
17% were Child-Pugh C. The prevalence of different NIS was high and 90 % 
reported one or more NIS. The most frequently reported symptoms for patients 
with malnutrition was abdominal pain, dry mouth, nausea, diarrhoea and changes 
in taste (Figure 9). 
Figure 9. Frequency of nutrition impact symptoms assessed by the Eating Symptom 
Questionnaire related to nutritional status according to the Global Leadership 
Initiative for Malnutrition criteria.
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Sixty seven percent of the patients reported eating two times or less per day and 
42% reported that their disease had affected the appetite for more than three 
months (Figure 10). 
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Figure 10. Frequency of nutrition impact symptoms assessed by the Disease 
Related Appetite Questionnaire (DRAQ) related to nutritional status according to the 
GLIM criteria.
*Statistically significant differences between groups
The following NIS were significantly associated with malnutrition according to 
the GLIM criteria: abdominal pain (p = 0.033), pain or ache affecting appetite (p 
= 0.034), changes in taste (p = 0.004), poor appetite (p = 0.010), varying appetite 
(p = 0.010), early satiety (p = 0.010), food tasting worse than when healthy (p = 
0.007) and for how long the disease had affected the appetite (p = 0.001). 
The NIS frequency from the ESQ was strongly negatively correlated with CLDQ 
(Pearson r -0.717, p < 0.001). All quality of life domains were significantly lower 
in the malnourished group. The median CLDQ in malnourished patients was lower 
than in well-nourished patients (1 score-point, 95% CI: -1.5, -0.5, p-value < 0.001). 
After adjusting for gender and Child-Pugh score, the difference in median CLDQ 
between malnourished patients and well-nourished patients was -0.7 score-point 
(95% CI: -1.1, -0.3, p-value 0.002).
Low HRQOL and reporting 4 or more NIS was more prevalent in patients with 
more severe liver disease (Figure 11).
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Figure 11. Malnutrition, Quality of Life and nutrition impact symptoms according to 
severity of liver disease (%)
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Malnutrition was present in 32% according to the GLIM criteria with the major-
ity fulfilling the phenotypic criterion reduced muscle mass according to ASMI 
measured with DXA. The prevalence of low ASMI was 23% and 11% had a 
MAMC in the lowest percentile. Sixty eight percent were classified as SGA A 
(well-nourished), 23% as SGA B (suspected or moderately malnourished) and 
8% as SGA C (severely malnourished). When comparing between the different 
Child Pugh groups, low MAMC and SGA B/C were more prevalent in patients 
with Child Pugh C, and low ASMI and malnutrition according to GLIM was most 
prevalent in Child Pugh B (Figure 12).
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Figure 12. Prevalence of malnutrition and muscle mass depletion according to dif-
ferent assessment tools in the different Child-Pugh classes (%)
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6.5.1 Not in the published paper
A sample from the Swedish general population (n=506) filled in the ESQ and 
DRAQ. This group was a representative sample of the Swedish population between 
18-80 years old but was different from patients with chronic liver disease regarding 
age (in median 46 years) and gender. In this national sample, 77% reported one or 
more symptoms. The age group 18-24 and 25-29 reported more symptoms than 
the older age groups. The sample was intended to serve as control group for the 
chronic liver disease cohort but because of the skewed age and gender distribution 
compared to the population with chronic liver disease, it was not deemed appropri-
ate to present distribution for each symptom. When comparing the control group 
from the general population with a multinomial logistic regression, the following 
symptoms were more frequent in patients with chronic liver disease after adjusting 
for age: abdominal pain (p=0.002), diarrhoea (p=0.001), dry mouth (p=<0.001), 
poor appetite (p=<0.001), my appetite varies from day to day (p=0.006), food 
tastes bad (p=0.008) and my eating varies from day to day (p=0.001). 
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6.6 Study IV
In total, 143 IC measurements performed in median on postoperative day (POD) 
6 (IQR 3), were retrospectively analysed. The mean mREE was 1950 ± 461 kcal 
(range 720-3309 kcal) or 24.5 ± 6.1 kcal/kg body weight. There were significant 
differences for absolute values in REE between men and women, whereas there was 
no significant difference in mREE between men and women when adjusted for body 
weight (24.8 ± 6.1 vs. 23.9 ± 6.2 kcal/kg body weight, p=0.440). Hypermetabolism 
was present in almost half of the population (49%) and was defined as a mREE 
>120% of what was predicted with the Harris & Benedict equation.
There was a low accuracy of HB and of fixed factors. The highest accuracy rate 
in patients with a BMI <25 kg/m² was achieved when the fixed factor 35 kcal/kg 
(47%) was applied; the HB equation predicted REE accurately (± 10% of mREE) 
in 18% of these patients. The fixed factor 30 kcal/kg had the highest accuracy 
rate in patients with BMI 25-29.9 (39%) and the fixed factor 25 kcal/kg (30%) 
for patients with BMI ≥30. 
Bland-Altman analysis between mREE and the prediction of energy expenditure 
and energy requirement showed wide limits of agreement. The lowest mean dif-
ferences, -95 kcal, was for the fixed factor 30 kcal/kg body weight, although the 
95% CI was between -1268 to 1077 kcal (Table 7).
Table 7. The limits of agreement between the methods: Bland-Altman analysis
Difference for formula, kcal Mean SD -1.96 SD +1.96 SD
mREE - Harris & Benedict 256 398 -524 1035
mREE x 1.2 – 25 kcal/kg 311 564 -795 1417
mREE x 1.2 – 30 kcal/kg -95 598 -1268 1077
mREE x 1.2 – 35 kcal/kg -501 436 -1760 757
mREE – new equation 1.9 349 -682 686
mREE; measured resting energy expenditure, SD; standard deviation, kcal; kilocalories
Concordance between mREE and HB equation and the fixed factors was low 
(Table 8).
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Table 8. Concordance between measured resting energy expenditure and predicted 
resting energy expenditure and fixed factors
Method CCC 95% CI r2
Harrris & Benedict equation 0.350 0.248, 0.445 0.26
25 kcal/kg body weight 0.254 0.130, 0.371 0.11
30 kcal/kg body weight 0.317 0.167, 0.453 0.11
35 kcal/kg body weight 0.231 0.116, 0.339 0.11
New equation 0.605 0.505, 0.689 0.42
CCC; Lin’s concordance coefficient, CI; confidence interval, r2; Pearsons r squared
In a multivariate linear regression, surgery time and male gender increased mREE, 
while age, MELD score and cold ischemia time decreased mREE (Table 9).
Table 9. Factors independently related to measured resting energy expenditure in 
multivariate linear regression.
Variable Coefficient 95% CI P-value
Age -10.9 -15.8, -5.9 <0.001
Gender 272 76, 468 0.007
MELD day 0 -13.9 -24.7, -3.1 0.012
Surgery time 1.12 0.33, 1.92 0.006
Cold ischemia time -0.62 -1.08, -0.20 0.011
CI: confidence interval; IC: indirect calorimetry; MELD: Model for End-Stage Liver Disease; kg: 
kilogram
A new equation was derived that included age, gender, body weight on day of IC, 
surgery time in minutes, cumulative dose of steroids/body weight, cold ischemia 
time in minutes and MELD score. All variables contributed significantly and 
accounted for 42 % of the variability observed in mREE. The resulting predictive 
equation was the following:
REE = 2059.6 + (add 344.7 if male) + (1.3 x surgery time) + (5.4 x weight) – (11.6 
x age) – (11.8 x MELD) – (11.6 x cumulative dose of steroids divided by body 
weight) – (0.7 x cold ischemia time)
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where surgery time and cold ischemia time are in minutes, weight is body weight 
(kg), age is in years, MELD score on the day before transplantation (MELD is 
derived from weighted scores for creatinine, INR and bilirubine), cumulative dose 
of steroids is intravenous steroids postoperative day 1- 5 divided by body weight. 
The new equation showed a higher concordance than HB and fixed factors: Lin’s 
concordance correlation (CCC= 0.605, 95 % CI 0.503-0.689) (Table 8). 
The low accuracy of HB, the new equation and the fixed factors suggest that REE 
should be measured with IC early after liver transplantation in order to reduce the 
risk of both under- and overfeeding individual patients.
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7 DISCUSSION
7.1 Results discussion
There have been significant advances in nutritional assessment research in patients 
with chronic liver disease during the years since the studies included in this thesis 
were designed. CT is now an established body composition measurement method 
recommended by both EASL and ESPEN to measure muscle mass depletion if 
a CT scan is available. Still, many methodological questions remain. This the-
sis has contributed with an understanding of DXAs role in assessment of body 
composition in chronic liver disease: FFMI is associated with infections after 
liver transplantation (Study I), ASMI measured by DXA is correlated with SMI 
measured by CT (Study II) and identified reduced muscle mass in Study III. We 
found that NIS were prevalent in patients with chronic liver disease and associated 
with malnutrition and worse HRQOL (Study III). REE should be measured after 
liver transplantation instead of calculating energy requirements to avoid under or 
overfeeding after liver transplantation (Study IV). Some of the results in this thesis 
warrant further discussion.
7.1.1 Identifying malnutrition and muscle mass depletion
The focus in Study I-III was to study malnutrition or muscle mass depletion, 
although assessment of nutritional status in general was also explored to some 
extent. In most national guidelines in Sweden, as well as international guidelines 
on how to screen or diagnose malnutrition, BMI is mentioned (14, 155, 157, 158). 
EASL recommends to assume that malnutrition is present if BMI is < 18.5 kg/m2 
(39) although such cases were rare in our cohort. In the four studies in this thesis, 
the prevalence of a BMI below 20 kg/m2 was only 4-8%. Even so, the prevalence 
of malnutrition and/or muscle mass depletion was markedly higher indicating that 
BMI is not useful as a marker of malnutrition in patients with chronic liver disease 
under liver transplant evaluation. BMI is affected by fluid accumulation and in 
patients with pronounced ascites and oedema BMI can be falsely high. Sarcopenia 
was not investigated because of the lack of data on muscle strength or functional 
parameters. The prevalence of muscle mass depletion in our studies (15-40%, Table 
5) was lower compared to those of other studies (68-76%)  (23, 35, 110), although 
it is important to acknowledge differences in severity of liver disease, country of 
origin and methodology. The large range in prevalence of muscle mass depletion 
in our studies confirms the results from previous studies where the prevalence is 
highly dependent on the method used (100). 
DXA was used to study body composition even if the method has some limita-
tions, especially in patients with fluid accumulation. The prevalence of patients 
with malnutrition in Study I was lower than reported in Study II and III. This can 
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be attributed to the use of whole-body composition parameters which may be 
affected by ascites. Because of the retrospective nature of the study, the analysis 
of the nutritional assessment by dietitians in Study I suffered from methodological 
problems. Many factors that are normally considered (e.g. dietary intake, anthro-
pometric measurements) were not available. 
An assessment of sarcopenia is recommended in patients with cirrhosis by either 
DXA or CT according to the newly published guidelines by ESPEN and EASL 
(39, 60). The main aim in Study II, was to study inter-method correlations between 
DXA and CT Study II demonstrated that ASMI and SMI are correlated, also in 
patients with ascites. However, FFMI measured by DXA was not correlated with 
SMI or ASMI in patients with ascites. This finding suggests that FFMI measured 
with DXA is not an accurate measurement to determine body composition in 
patients with ascites but that ASMI can be used. 
The GLIM criteria were used to diagnose malnutrition in Study III in which 32% 
of the population was classified as malnourished. The GLIM criteria still need 
further validation in prospective studies. GLIM is however promising because it 
includes reduced muscle mass as phenotypic criterion. In patients with ascites and 
fluid accumulation, weight loss and BMI as phenotypic criterions are not appro-
priate, and in those patients malnutrition can instead be identified by measuring 
muscle mass. 
7.1.2 Influence of fluid accumulation on nutritional assessment
The main limitation in nutritional assessment of patients with liver cirrhosis or 
post-transplantation is fluid accumulation, both in the form of ascites and peripheral 
oedema. In healthy subjects, the average amount of water is 73.2% in the body. In 
cirrhosis, even in the compensated state, it is common to have an increased amount 
of extracellular and intracellular water (159). Hydration status has been evaluated 
in a few studies in patients with cirrhosis. Strauss et al. measured hydration status 
with isotopic dilution technique and found both sexes to be overhydrated (76.1% 
in men and 77.6% in women compared to the normal value of 73%), and women 
were significantly more overhydrated than men (38).
The EASL guidelines recommend adjusting body weight by calculating dry weight 
and dry BMI if ascites and/or oedema is present (39). It was difficult to account 
for fluid accumulation in a structured way because of the retrospective nature of 
Study I, II and IV. This is a limitation in our studies and reflects the difficulties of 
nutritional assessment in this patient group. Clinicians rarely have the technology 
to assess fluid accumulation in an accurate way. 
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In Study II, ASMI was associated with SMI even in patients with ascites while 
FFMI was not. Our results suggest that in patients with ascites, ASMI can be used 
to measure body composition, but FFMI is not recommended. A few studies have 
evaluated how DXA perform before and after paracentesis in patients with cirrhosis. 
A small study assessed total body composition, and found that DXA measurement 
provided a lower lean mass value after paracentesis which was proportional to 
the amount of drained ascites (160). One study evaluated bone density before and 
after paracentesis and found no difference in bone density in whole body meas-
urement although there was significant difference in the spine and the hip. The 
authors suggest that ascites could influence the measurement over the abdomen 
but not the rest of the body (161). The fluid accumulation in patients with cirrho-
sis is not only ascites; oedema in the lower limbs is also prevalent. Sinclair et al 
found that reduced upper limb lean mass was most strongly associated with wait-
ing list mortality compared with total or lower limb lean mass (37) and a possible 
explanation could be that fluid accumulation in the lower limb gives false results. 
The effect of fluid accumulation on CT segmentation has not been accounted for 
in most previous studies. Overhydration may expand muscle volumes and thereby 
affect the assessment of sarcopenia, and overhydration was found to significantly 
affect the measurement of cross-sectional muscle area in a recent study (109). 
7.1.3 Gender disparities in chronic liver disease and body 
composition
The gender distribution in the studies included in this thesis was between 64-74% 
male and 26-36% female, which is in accordance with most Western countries were 
women represent approximately 30% of liver transplantation recipients (162). The 
distribution in our cohorts can to some extent be explained by the high proportion 
of patients with PSC which in the Nordic countries is the leading indication for 
liver transplantation (82), PSC is a disease where 2 out of 3 are male. The gen-
der disparities in chronic liver disease are to some extent explored in previous 
research. The progression of fibrosis in patients with chronic hepatitis C is faster 
in men compared to women (163). In a Chinese cohort, men were 2.08 times more 
likely to develop more severe liver disease compared with women (95% CI 1.66-
2.61) even after controlling for lifestyle and environmental exposures (164). In 
an Italian cohort of 12200 patients with chronic liver disease, the male to female 
ratio was 1.4, although the prevalence of cirrhosis was not different between men 
and women (21.4% vs 22.2%) (165). In contrast, The National Board of Health 
and Welfare in Sweden reported that men were 2.5-2.7 times more likely to die 
from liver cirrhosis than women during the years 1992-2001 (166, 167).
The current understanding of differences in body composition between men and 
women is still limited. It is important to have nutritional assessment tools that 
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identify all patients at risk, irrespective of gender or ethnicity. We found gender 
differences in the prevalence of muscle mass depletion and malnutrition in Study 
I-II. In Study I there was a marked difference with men having more muscle mass 
depletion and women more fat depletion, i.e. adipopenia. Our findings are in line 
with previous reports that the characteristics of tissue loss are different in men 
and women with cirrhosis, where sarcopenia is more common in men and women 
more often present with fat depletion (30, 31). Peng et al showed that men lost a 
higher proportion of their body protein than women, irrespective of disease severity 
(168). In the Nordic countries, female liver transplant recipients have a 7% lower 
risk of death than men (hazard ratio 0.93, 95% CI 0.88-0.98) (82). The Nordic 
results are different from other countries: although the prevalence of muscle mass 
depletion correlates with post-transplant mortality and muscle mass depletion is 
higher in male pre-transplant candidate, post-transplant survival is not different 
between genders (21, 51).
The cause of the different distribution of adipose tissue and muscle mass between 
men and women is not fully understood. The liver has an important role in sex hor-
mones regulation and alterations in advanced liver disease may play a role. One of 
the few randomised controlled trials performed to treat sarcopenia was conducted 
with intramuscular testosterone treatment for 12 months to male patients with 
cirrhosis. Patients who received testosterone increased their muscle mass (169).
In Study III there was a tendency for women to report more NIS than men (p=0.05). 
No difference was found in prevalence of malnutrition or in HRQOL between men 
and women. Zambrano et al used the patient-generated SGA to determine malnutri-
tion and found women to be more malnourished than men, although muscle mass 
depletion measured with CT was more common in men (170). Potential differences 
in prevalence of malnutrition between genders have not been explored in detail 
in research, presumably because of the lower frequencies of women with severe 
liver disease which often make such analyses under-powered. 
7.1.4 Outcome after liver transplantation
The result from Study I shows that a low FFMI is associated with an increased 
risk of severe infections within the first post-transplant month. Our results are in 
accordance with previous research in which severe malnutrition was associated 
with infections after liver transplantation (171). The most common causes for long 
term mortality after liver transplantation are malignancy, cardiovascular disease 
and infection (172). 
Length of stay (LOS) is sometimes used as a quality metric (173) and was used as 
a variable in Study 1. We found that post-operative dialysis (P = 0.004) and post-
operative infections (P < 0.001) were significantly associated with LOS in hospital 
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but body composition was not. LOS could be argued to be a financial metric and 
not a quality metric and is influenced by many factors, although reducing LOS 
could potentially reduce the risk of in-hospital infections which is beneficial for 
the patient. When comparing data from our study to others, we speculated that 
LOS could be affected by differences in health care organisation. Different prac-
tises for rehabilitation exist in different centres and countries. In the US it is com-
mon for patients to go to rehabilitation facilities while in the UK the patients tend 
to stay for rehabilitation in the hospital. At our transplant centre, patients from 
external regions are often discharged to the home hospital while patients from 
the transplant region either go to rehabilitation facilities or may stay longer at the 
transplant centre. The parameter LOS does not provide information of resource 
utilisation after discharge. A short LOS should preferably be weighed against the 
potentially risk of higher readmission rates. Readmission rates were not analysed 
in Study 1 or Study IV. 
Assessment methods that provide information about body composition can be valu-
able to identify patients at risk of adverse outcomes (171). In a recent meta-analysis 
of different nutritional assessment tools, the different tools that identified a higher 
risk of pre-transplant mortality were: TSF risk ratio (RR) 2.15 (95% CI 1.5-3.07), 
MAMC RR 2.51 (95% CI 1.53-4.1), and CT RR 2.34 (95% CI 1.64-3.36) (11). 
In the studies included in this thesis, mortality was not analysed because of the 
high survival rate in our centre, which precluded meaningful statistical analyses.
7.1.5 Nutrition impact symptoms and quality of life
In Study III, 90% reported one or more NIS and 51% reported four or more NIS. 
Malnourished patients reported more NIS. Certain NIS, such as pain, poor appe-
tite, changes in taste and early satiety, were associated with malnutrition. The 
high prevalence of NIS in patients with chronic liver disease is a unique finding 
because our study was the first to consider the full spectrum of symptoms that can 
affect eating. The high prevalence of NIS and the association with malnutrition 
and HRQOL support the idea that NIS should be routinely assessed in patients 
with chronic liver diseases. The study does not present causality, although it could 
be hypothesised that treatment of NIS may work as a preventive action to avoid 
malnutrition to develop. Previous studies have mainly focused on gastrointestinal 
symptoms. In a study aimed at identifying patient-perceived to these interventions, 
patients with Child Pugh B and C liver cirrhosis (174) reported that barriers for 
an adequate nutritional intake were low energy, pain/illness, nausea/vomiting and 
ascites . Only 56% had a good appetite and 53% could eat an entire meal. Up to 
80 % of patients with liver cirrhosis report one or more gastrointestinal symptoms 
(175). The most common reported symptoms were abdominal bloating, abdomi-
nal pain, belching, diarrhoea and constipation. Gastrointestinal symptoms were 
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associated with recent weight loss and impaired physical and mental health-related 
quality of life in patients with liver cirrhosis (62). 
When planning health care resources, it is important to know the prevalence of 
adverse outcomes that might need additional resources to prevent or to treat. For 
an individual patient it might not always be necessary to be exact on whether the 
patient is suffering from malnutrition, sarcopenia or muscle mass depletion. The 
important factors could be how the patient is feeling and what affect the disease 
has on daily life and prognosis. 
We examined associations between NIS, malnutrition and HRQOL in Study III 
and found that malnutrition was significantly related to a worse quality of life. The 
frequency of NIS according to the ESQ was strongly negatively correlated with 
HRQOL according to CLDQ. Our result are consistent with a previous Swedish 
study on patients with liver cirrhosis, where gastrointestinal symptoms were asso-
ciated with recent weight loss and impaired HRQOL (62). The negative impact of 
malnutrition on HRQOL has been described by several studies (130, 132, 176). 
There have been few investigations on nutritional interventions and their effect 
on HRQOL in patients with liver disease. In a study of patient with liver cirrhosis, 
a late night snack with 200 extra kcal improved general health perceptions, role-
emotional and mental health components in a one year long intervention (177). In 
a 6 month long randomised intervention study on patients with liver cirrhosis, one 
group received nutritional therapy aiming at 30-35 kcal/kg and 1.0-1.5 gram veg-
etable protein/kg. The intervention group had a higher increase in HRQOL (106). 
Our results in Study III highlight the importance of identifying NIS since a high 
frequency of NIS is a risk factor for low HRQOL. Whether treatment of NIS 
would also improve HRQOL in patients with liver disease needs to be explored 
in future research.
The prevalence of NIS in a general population has not been systematically explored 
before. In our (unpublished) study on 506 statistically representative Swedes, we 
found that NIS were surprisingly common in the general population. The ques-
tionnaires were sent out during the flu season in January and February and we 
speculate that different viral diseases during the time period may have significantly 
reflected on our findings. Preferably, the study should be repeated in e.g. early 
autumn before we draw any further conclusions about the prevalence of NIS in 
the general population. A previous study of self-reported somatic and psychologi-
cal symptoms showed that women reported higher total symptom prevalence than 
men and a trend was found showing an increase in symptom reporting from 1985 
and onwards (178). A study aiming at investigating trends in self-reported gen-
eral health, showed that the risk of having ≥3 symptoms increased significantly 
from 2000 to 2016 (179). The increases in symptoms were significantly higher 
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in young and individuals with lower education (179). This is in accordance with 
our observation that the younger population reported more symptoms. Another 
Swedish study investigated gastrointestinal symptoms in patients with hereditary 
transthyretin amyloidosis after liver transplantation and compared frequency of 
symptoms with patients liver transplanted due to end-stage liver disease as well as 
healthy controls. Symptoms was evaluated with The Gastrointestinal Symptoms 
Rating Scale. The prevalence of GI symptoms was higher in patients with heredi-
tary transthyretin amyloidosis than in healthy controls but equal to that of trans-
planted controls (180).
The high frequency of symptoms reported by patients with chronic liver disease 
suggest a potential to improve patients HRQOL if the symptoms are treated. 
According to my clinical experience, some symptoms are barriers for implement-
ing nutritional interventions and the results from Study III confirms an association 
with NIS and malnutrition and HRQOL.
7.1.6 Energy requirement after liver transplantation
In the immediate post-transplant phase, it is routine practice at our transplant centre 
to receive medical nutrition therapy. Study IV was designed to increase our under-
standing of energy expenditure after liver transplantation in order to enable optimal 
nutritional therapy. Malnutrition and eating difficulties are prevalent in the liver 
transplant candidate (181) and previous research demonstrated that early enteral 
nutrition is associated with fewer viral infections (182). Energy supply needs to 
be balanced towards the patients total energy expenditure (TEE), which includes 
REE, food-related thermogenesis and energy expenditure related to physical activ-
ity (39). A recent study of energy balance demonstrated that 77.8% of measured 
energy requirement was met between the 7th and 10th day after liver transplanta-
tion (183), however only 6.9% had enteral nutrition to support the energy intake. 
There has been a lot of debate on whether to provide a hypocaloric or isocaloric 
feed in ICU-patients (184). This has however not been explored in detail in liver 
transplantation. Kyoung et al advise to provide a lower amount of energy (<18 
kcal/kg.BW/d) during the first 48 h postoperatively (185). A reason for the lack 
of data on how much energy should be supplied during the different phases after 
liver transplantation could be the scarcity of data on REE in the liver transplant 
recipient. Earlier studies report conflicting data on REE in patients early after liver 
transplantation. Two studies on 14 patients and 16 patients showed no significant 
changes in REE before and after LT (144, 186). However, hypermetabolism before 
transplantation has been found to be associated with hypermetabolism after liver 
transplantation in other studies (187, 188). Plank et al showed that REE was sig-
nificantly elevated after LT with the highest REE on POD 10 in a study on 14 
patients with repeated measures of REE before surgery and up to 1 year after liver 
transplantation (189).
50
In Study IV, we found that the HB equation for predicting REE, as well as the 
fixed factors suggested in the ESPEN and EASL guidelines, provided estimates of 
energy requirement that were far too inaccurate to be of clinical value. Other studies 
have demonstrated predictive equations to be within 90–110% of mREE in only 
45% patients with cirrhosis (190), and to be correct in around half of hospitalised 
patients (191). The difficulty to construct a population specific prediction formula 
has been described in other studies, where a formula for e.g. patients with cirrhosis 
accounted for 61% of the variation (192). Even if our own attempt to construct a 
predictive equation had a higher concordance than both HB and the fixed factor 
in our population, it had a high variability between patients and can therefore not 
be recommended for clinical use. Studies of predictive equations compared with 
IC have been performed in other patient populations (193, 194) and the findings 
from those studies confirm the difficulties in predicting REE. 
Our findings in Study IV suggest that indirect calorimetry should be used to measure 
REE early after liver transplantation to prevent under- or overfeeding. It could be 
argued that it is not feasible to measure REE on all patients. Liver transplantation 
involves many procedures and significant costs to which IC would add relatively 
little. It is possible that the benefits from providing adequate amounts of energy 
to help the patient recover faster would rather be cost-effective. It may in theory 
reduce the LOS and other complications after the surgery. Previous research shows 
that early enteral nutrition after liver transplantation gives a lower rate of viral 
infections (182). 
7.2 Methodological considerations
7.2.1 Study design
Studies can be either observational or experimental. The studies in this thesis are 
observational studies. Study I, II and IV are cohort studies. A cohort study is a 
good study design to explore etiological questions. A cohort is a group of people 
sharing the same experience, in this case a liver transplantation where time is a 
parameter. In Study I muscle mass was studied before liver transplantation and 
compared to what happened after the surgery (e.g. the exposure). In Study IV the 
purpose was to measure the prevalence of the “disease” i.e. abnormal metabolism 
within our cohort. The main limitation in Study IV was the lack of baseline REE 
before surgery which limits the possibility to draw conclusions about causality 
between different factors associated with liver transplantation and mREE. To reduce 
this limitation, HB was used for comparison, HB was however developed from a 
healthy population (58). Study III was a cross-sectional study of patients during 
their pre-transplant evaluation and patients with malnutrition were compared to 
patients without malnutrition. 
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7.2.2 Generalisability
Several aspects need to be considered regarding generalisability of the results from 
the four studies in this thesis. The different study cohorts represent heterogenous 
groups of patients with chronic liver disease and liver cirrhosis with different aeti-
ologies. The populations included in the four studies are somewhat different from 
other transplant centres in the world. Our population in the different studies consists 
of 30-51% Child-Pugh A, 39-48 % Child-Pugh B and 17-31% Child-Pugh C and 
a median MELD score of 11-13. The high proportion of Child-Pugh A patients 
(for liver transplant cohorts) is explained by many having HCC or PSC as main 
transplant indication. This is also shown in the high proportion of patients with 
autoimmune diseases, between 31-40%, which is slightly higher than previously 
reported in the Nordic Countries (172). Sweden has relatively short waiting times 
and low wait list mortality, which contributes to many patients without severe 
decompensation being transplanted. The disease severity in the patient group under 
investigation needs to be considered, since prevalence of malnutrition and sarco-
penia is closely linked to severity of liver disease. In Study III, the study cohort 
consists of patients under evaluation for liver transplantation. All were able to fill 
in questionnaires, which may result in a selected consenting non-encephalopathic 
Swedish-speaking sample of patients with chronic liver disease. The results may 
therefore not be generalised to all patients with chronic liver disease. 
The choice of different cut-offs in the studies is a consequence of the evolving field 
of body composition research. It is important to acknowledge this aspect when gen-
eralising our results to other populations. The cut-offs of below 5th percentile was 
used for FFMI in Study I and below 10th percentile in Study II. The data analysis 
for Study I was performed in 2013-2014 while the analysis for Study II was done 
2016-2017. In 2015 the ESPEN guideline for Diagnostic criteria for Malnutrition 
(155) was published, where non-age adjusted cut-offs for FFMI were suggested. 
The 10th percentile cut-off in Study II was chosen because it was more similar 
to the cut-offs suggested in the ESPEN guideline. Muscle mass varies across the 
lifetime and is generally decreasing with age. The EWGSOP therefore recommend 
the use of normative references (healthy young adults) whenever possible, with 
cut-offs set at −2 standard deviations compared to the mean reference value (17). 
In contrast to these recommendations, no age-adjusted cut-offs are available for 
SMI. To enable comparisons with other populations, the cut-offs suggested by 
EWGSOP and GLIM were used for ASMI in Study III even though they are not 
age adjusted. The varying prevalence of malnutrition and muscle mass depletion 
in the different studies in this thesis reflect the difficulties in the field of nutri-
tional assessment. There is little recently published data on healthy individual´s 
body composition and there is a lack of Nordic reference data. Sweden had an 
increased immigration in this millennium, which also reflects on liver transplan-
tation cohorts. A recent study showed that immigration increased the incidence 
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of HCC and the need for active treatment such as liver transplantation in Sweden 
(195). Body composition varies in different parts of the world. Ethnicity should 
therefore be considered when choosing cut-offs for low muscle mass or fat mass. 
It could be argued that it is not always relevant to compare patients with chronic 
diseases with healthy individuals. Comparisons should rather be done with the 
ideal body reserves that are needed to withstand the consequences of the disease 
or interventions (e.g. transplantation). This approach was used in Study I where 
FFMI and FMI were analysed as continuous variables in the multivariate analysis.
7.2.3 Aspects that may affect validity
Systematic errors such as selection bias, information bias and confounding can 
affect results. Bias creates associations that are not true, and confounding describes 
an association that is true, but the interpretation of the association is wrong (196). 
The low number of women in the four studies affects the gender-specific statisti-
cal calculations, which in turn could affect the external validity. However, this 
reflects liver transplant populations in general in which the male gender is over-
represented (162).
7.2.3.1 Validity in data sources
The different data sources in this thesis have different advantages and disadvan-
tages, as shown in Table 1. Manufacturers of DXA machines have developed dif-
ferent models and software versions which need to be considered when comparing 
validity of body composition measurements (28). A limitation in Study II is the 
use of CT scans performed for clinical purposes, both contrast enhanced scans 
and unenhanced scans. Previous research has shown that SMI is increased by up 
to 2.8%  with the use of contrast medium (197, 198). CT scans performed with 
different tube voltages have also been included in this thesis, both 100 kV and 
120 kV. It is unknown to what degree this may have affected the results. In a study 
comparing scans with 80 kV and 140 kV, SMI was 5.2% lower with 80 kV (199). 
There are also several different software programs in use for CT segmentation. In 
Study II Image J was used. Most studies on patients with cirrhosis use the software 
program SliceOmatic. A comparison of segmentation using different programs has 
however shown excellent agreement between different software (200). Our use 
of Image J should therefore not preclude comparisons of our results with those 
from other studies.
Data from questionnaires are self-reported and include some limitations, such as 
the uncertainty about how the participant interpreted the questions. The group 
which developed the questionnaires ESQ and DRAQ (70) explored the patients 
interpretations of the questions during the development process in order to limit 
the risk of individuals interpreting the questions in different ways. The use of 
information collected from medical charts may provide inaccurate information 
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because medical personal could have mis-recorded information. Data quality 
includes uncertainty in data accuracy, completeness, consistency, credibility, and 
timeliness (201). These potential limitations have to some extant been dealt with 
in the statistical analysis from using multivariate analysis when possible.
7.2.3.2 Selection bias
Selection bias can arise when there are differences in groups regarding how they 
were included in the study. In Study I-II, the study population consists of patients 
with a DXA measurement performed at Karolinska University Hospital during the 
liver transplantation evaluation. There is a theoretical risk of selection bias, in that 
the patients with a DXA done elsewhere could potentially have differed in mus-
cle mass compared to the patients who had a DXA scan performed at Karolinska 
University Hospital. Study II has a higher proportion of HCC than some other liver 
transplant cohorts. It is more common for patients with HCC to have a CT at our 
centre, which potentially could affect the prevalence of muscle mass depletion. 
It is, however, unlikely that it affected the main aim of the study which was to 
perform inter-method comparisons between DXA and CT.  In Study III there is a 
risk of selection bias if patients reporting NIS could be more inclined to partici-
pate in a study that investigates their current problems. In Study IV, patients with 
certain characteristics were included, e.g. the healthier subjects that were able to 
have the IC measurement. Also, the staff at the ward were not able to perform a 
measurement when the workload was heavy which could influence the selection 
of patients. The cohort is not representative of all liver transplanted patients. That 
the results from this study will only be generalisable to certain patients after a 
liver transplantation was clearly stated in Study IV.
7.2.3.3 Information bias
Misclassification can occur from systematic errors of the study variable measured 
(196), for example if participants are classified as malnourished or not malnourished. 
The misclassification can be differential where there is different misclassification 
between groups or non-differential where the misclassification is equal between 
groups. To overcome the uncertainty involved in the retrospective analysis in Study 
I, any weight loss over 10% in combination with eating difficulties was used to 
define malnutrition, since it was not always clear if the weight loss was voluntary 
or involuntary. To avoid misclassifying patients as malnourished when they were 
not, a strict definition was used. This instead involves a risk of some patients being 
stratified as “at risk of malnutrition” when other criteria could have stratified them 
as malnourished. In Study III, there is a low risk of non-differential misclassifi-
cation (between the groups malnourished and not-malnourished patients), since 
weight loss had to be recalled from the patient if no earlier weight was available 
in the medical chart. The influence of ascites on weight also introduces a risk of 
misclassification.
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7.2.3.4  Confounding
A confounder is a parameter that is associated with both the exposure and the 
outcome, but the association is not in the causal pathway (196). Adjustments for 
potential confounders were made within the statistical analyses and the confound-
ers were adjusted based on previous knowledge from the literature as well as on 
clinical experience. In Study I, the logistic regression model for the outcome vari-
able post-operative infections was adjusted for many variables including age, sex, 
body composition and different pre and post liver transplantation parameters. In 
Study II, inter-method correlation was tested in both patients with and without 
ascites. In the multinomial logistic regression analysis in Study III, we adjusted for 
sex, Child-Pugh class, and ascites, which are potential confounders. In Study IV, a 
multiple linear regression analysis was performed to test if transplantation specific 
factors affected REE. Also, the previously known factors weight, height, age and 
gender were included in the regression analysis to clarify how much these known 
confounders contributed to REE. However, the potential risk of unmeasured and 
unknown confounders cannot be fully disregarded in the four studies in this thesis.
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8 CONCLUSIONS AND CLINICAL 
IMPLICATIONS
In this thesis, different aspects of nutritional assessment in patients undergoing 
liver transplantation evaluation and liver transplantation have been described and 
analysed. From the studies included in this thesis, we conclude that:
Body composition should be assessed during pre-transplant evaluation
• FFMI is associated with infections early after liver transplantation
• When assessing body composition, ASMI by DXA or SMI by CT are 
preferable 
• The proportion of muscle mass depletion varies with assessment method 
and gender
NIS should be routinely assessed in patients with chronic liver diseases 
• NIS are common in patients with chronic liver disease and patients with 
multiple symptoms are more likely to be malnourished and have worse 
quality of life
• Certain symptoms, such as pain, poor appetite, change in taste and early 
satiety are associated with malnutrition
Indirect calorimetry to measure energy expenditure is recommended for estimating 
energy requirements after liver transplantation
• Resting energy expenditure is often increased early after liver transplantation
• Estimates of energy expenditure were inaccurate in most cases when com-
pared to measured energy expenditure
In clinical practise many different factors, such as accessibility to body compo-
sition technology as well as economical and organisational resources, affect the 
possibilities to implement the above recommendations. NIS can be screened for in 
a quick and cost-effective way, for example by sending the patients questionnaires 
before the visit. More resource is needed in order to treat identified symptoms. 
When it comes to assessing body composition and resting energy expenditure, my 
personal conclusion from completing my PhD-studies is something that far more 
renowned persons have said before me: “The more I learn, the more I realise how 
much I don’t know”. What I do know, is that nutritional assessment in patients 
with liver disease is important, muscle mass should be objectively measured and 
there is still much to learn.
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9 FUTURE PERSPECTIVES
Many new questions have arisen during the completion of the four studies and the 
writing of this thesis. Some specific areas of interest are:
• CT to measure muscle mass in patients with chronic liver disease is now an 
established method in research. It is unlikely that the majority of transplant 
centres around the world will have resources to perform repeated CT 
measurements. There is still little knowledge on how much exercise and 
how long of a period of improved nutrition is needed to increase muscle 
mass. I would like to design a study to explore how muscle mass deple-
tion evolves during the progression of the liver disease and in conjuction 
with nutrition therapy. There is a need for intervention studies to explore 
how long it takes to increase muscle mass and whether CT and/or more 
clinically available methods such as hand grip strength measurements are 
reliable ways to measure the increase.
• With the results from Study III, we hypothesise that early identification 
and treatment of NIS can prevent malnutrition and improve HRQOL. 
An interventional longitudinal study could test this hypothesis. I would 
like to conduct a prospective study of how NIS evolve during different 
phases of liver disease; at diagnosis of chronic liver disease, in cirrhosis 
and when decompensation develops.
• Even if I did not explore this specifically, the results in Study IV suggest 
that energy requirements in patients with PSC are different from other 
patients with chronic liver disease. I would like to investigate whether 
this observation is explained by the PSC liver disease or by other factors 
such as as age, muscle mass or comorobidity such as inflammatory bowel 
disease. 
• We are just beginning to understand how liver cirrhosis and sex hormones 
affect the body composition of men and women. Further exploration 
of gender differences in body composition is warranted. Do we need 
gender-specific assessment tools in addition to gender-specific cut-offs? 
• Most of all I want to ask patients about what matters to them. This thesis 
was built on my frustrations as a dietitian. I am certain that my patients 
would choose different areas to study. Body composition is important 
in order to identify patients at risk of adverse outcome, and survival 
is important for people with life-threatning diseases. HRQOL has not 
received enough attention in research. What do the patients want?
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10 POPULÄRVETENSKAPLIG 
SAMMANFATTNING
Levercirros är en sjukdom som kan ge många olika typer av symtom. Det är vanligt 
att aptiten är nedsatt när man är sjuk och det kan då vara svårt att äta tillräckligt 
av alla näringsämnen som kroppen behöver. Levern har en viktig funktion i vår 
ämnesomsättning både när det gäller fett, protein och kolhydrater samt vitaminer 
och mineraler. En del av den energi vi får i oss när vi äter lagras i muskler och i 
levern i form av glykogen. Energin från maten vi äter varar bara i några timmar, 
efter det används den lagrade energin i levern som energikälla fram till nästa 
måltid. Vid svår leversjukdom kan inte levern lagra lika mycket energi.  Om levern 
töms på energi och det är långt till nästa måltid behöver kroppen hitta en alter-
nativ energikälla: fettväv och muskelmassa börjar brytas ned.  På grund av dessa 
svårigheter är det vanligt med undernäring hos personer med svår leversjukdom.
Det är också vanligt att samla på sig vätska i buken, ascites, och ödem i benen. 
Det leder till att vanliga sätt att mäta nutritionsstatus som viktförändring och BMI 
kan ge felaktiga resultat då en viktförändring kan orsakas av förändringar i vät-
skemängd och inte i faktisk kroppsmassa. Olika typer av vävnad förbrukar olika 
mängd energi. Muskelmassa förbrukar t. ex. mer energi än fettmassa och teoretiskt 
förbrukar inte vatten någon energi. Problemet med ansamlad vätska är också van-
ligt i det tidiga skedet efter en levertransplantation vilket påverkar möjligheten att 
korrekt kunna räkna ut energibehovet.
För att bättre kunna bedöma vilka patienter som är undernärda var ett syfte med 
denna avhandling att studera muskelmassa mätt med olika röntgenmetoder. Ett 
annat var att studera hur vanligt det är med symtom som påverkar förmågan 
att äta samt om dessa symtom är associerade med undernäring och livskvalitet. 
Ytterligare ett syfte var att jämföra uppmätt energibehov med olika sätt att räkna 
ut energibehov efter en levertransplantation.
I delstudie I studerade vi 109 patienter innan och efter en levertransplantation och 
fann att 2–20 % av patienterna var undernärda när de utreddes för transplantation. 
Förekomsten varierade beroende på kön och mätmetod. Mätt med dual energy 
x-ray absorptiometry (DXA) hade 20 % av männen och hos 5 % av kvinnorna 
en låg fettfri massa och bedömdes därmed som undernärda. Trettiofem (37 %) 
patienter utvecklade allvarliga infektioner inom 1 månad efter levertransplanta-
tion. Vi fann ett samband mellan mängd fettfri massa och förekomst av infektioner. 
Kroppsammansättning uppmätt med DXA under transplantationsutredningen ger 
värdefull information om nutritionsstatus hos patienter med levercirros.
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I delstudie II jämförde vi kroppssammansättningsmätningar gjorda med DXA 
och med datortomografi (DT) under levertransplantationsutredningen hos 53 
patienter. Tre olika mätningar jämfördes, fettfri masse index (helkropp) (FFMI)
och appendikulärt (muskler i armar och ben) skelettmasseindex (ASMI) från DXA 
och skelettmuskelmasseindex (SMI) mätt från DT. Nedsatt mängd muskelmassa 
hittades hos 45 % (SMI), 38 % (ASMI) och 30 % (FFMI) hos patienterna. När 
de olika metoderna jämfördes var likheten i mätresultatet starkast mellan ASMI 
och SMI. Hos kvinnor varierade förekomsten av nedsatt mängd muskelmassa från 
13 % till 50 % beroende på metod medan förekomsten var relativt lika mellan 
metoderna hos män, mellan 38 % och 43 %. ASMI mätt med DXA är ett bra och 
kostnadseffektivt mått för att mäta muskelmassa när DT inte finns tillgängligt hos 
levertransplantationskandidater.
I delstudie III studerades förekomst av symtom som kan påverka ätande hos 133 
patienter som utreddes för levertransplantation. Vi undersökte också om det fanns 
samband mellan symtom och undernäring och livskvalitet. Symtom som kan 
påverka ätande visade sig vara mycket vanligt: 90 % rapporterade ett eller flera 
symtom och 51 % rapporterade fyra eller fler symtom. De vanligaste symtomen 
var muntorrhet (61 %), buksmärta (58 %), diarré (45 %) och illamående (41 %). 
Trettiotvå procent var undernärda.  Patienter med undernäring rapporterade fler 
symtom och ju fler symtom desto lägre hälsorelaterad livskvalitet. Vissa symtom 
som smärta, nedsatt aptit, smakförändringar och tidig mättnadskänsla var associ-
erade med förekomst av undernäring.
I den sista studien, delstudie IV, studerades energibehov tidigt efter levertrans-
plantation. Olika riktlinjer rekommenderar olika sätt att räkna ut energibehov och 
beroende på vilken formel som används kan resultatet skilja sig åt. Det är viktigt 
att veta vilket energibehov en patient har efter levertransplantation för att kunna 
ordinera rätt mängd näring. För lite näring kan ge sämre läkningsförmåga och 
ökad risk för infektioner, för mycket näring kan stressa kroppen. Vi fann att det 
var en stor variation i uppmätt energibehov mellan olika individer. När det upp-
mätta energibehovet jämfördes med olika formler visade sig att formlerna inte var 
så bra på att förutspå energibehovet. Patienter med lång operationstid hade högre 
energibehov under återhämtningsperioden. 
Sammanfattningsvis visar resultatet från denna avhandling att andelen individer 
som bedöms som undernärda eller har nedsatt mängd muskelmassa varierar ber-
oende på vilken metod som används, symtom som kan påverka ätande är mycket 
vanligt och energibehov bör mätas och inte uppskattas efter levertransplantation.
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